{"lookup":"https://www.erudio.com/trials/{nct_id}.json","listing_floor":3,"schema_id":"erudio.trial_listing_index","schema_version":"1.0","trials":[{"commentary_sources":853,"json":"https://www.erudio.com/trials/ev-302-nct04223856.json","name":"EV-302","nct_id":"NCT04223856","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer","url":"https://www.erudio.com/trials/ev-302-nct04223856"},{"commentary_sources":784,"json":"https://www.erudio.com/trials/adaura-nct02511106.json","name":"ADAURA","nct_id":"NCT02511106","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.","url":"https://www.erudio.com/trials/adaura-nct02511106"},{"commentary_sources":758,"json":"https://www.erudio.com/trials/flaura2-nct04035486.json","name":"FLAURA2","nct_id":"NCT04035486","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)","url":"https://www.erudio.com/trials/flaura2-nct04035486"},{"commentary_sources":631,"json":"https://www.erudio.com/trials/monarche-nct03155997.json","name":"monarchE","nct_id":"NCT03155997","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer","url":"https://www.erudio.com/trials/monarche-nct03155997"},{"commentary_sources":618,"json":"https://www.erudio.com/trials/serena-6-nct04964934.json","name":"SERENA-6","nct_id":"NCT04964934","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","url":"https://www.erudio.com/trials/serena-6-nct04964934"},{"commentary_sources":560,"json":"https://www.erudio.com/trials/talapro-2-nct03395197.json","name":"TALAPRO-2","nct_id":"NCT03395197","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC","url":"https://www.erudio.com/trials/talapro-2-nct03395197"},{"commentary_sources":546,"json":"https://www.erudio.com/trials/cartitude-4-nct04181827.json","name":"CARTITUDE-4","nct_id":"NCT04181827","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/cartitude-4-nct04181827"},{"commentary_sources":516,"json":"https://www.erudio.com/trials/nct03036488.json","name":"NCT03036488","nct_id":"NCT03036488","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","url":"https://www.erudio.com/trials/nct03036488"},{"commentary_sources":502,"json":"https://www.erudio.com/trials/natalee-nct03701334.json","name":"NATALEE","nct_id":"NCT03701334","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer","url":"https://www.erudio.com/trials/natalee-nct03701334"},{"commentary_sources":501,"json":"https://www.erudio.com/trials/checkmate-816-nct02998528.json","name":"CheckMate 816","nct_id":"NCT02998528","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/checkmate-816-nct02998528"},{"commentary_sources":459,"json":"https://www.erudio.com/trials/db-06-nct04494425.json","name":"DB-06","nct_id":"NCT04494425","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","url":"https://www.erudio.com/trials/db-06-nct04494425"},{"commentary_sources":381,"json":"https://www.erudio.com/trials/mariposa-2-nct04988295.json","name":"MARIPOSA-2","nct_id":"NCT04988295","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","url":"https://www.erudio.com/trials/mariposa-2-nct04988295"},{"commentary_sources":373,"json":"https://www.erudio.com/trials/esopec-nct02509286.json","name":"ESOPEC","nct_id":"NCT02509286","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus","url":"https://www.erudio.com/trials/esopec-nct02509286"},{"commentary_sources":368,"json":"https://www.erudio.com/trials/nct03142334.json","name":"NCT03142334","nct_id":"NCT03142334","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)","url":"https://www.erudio.com/trials/nct03142334"},{"commentary_sources":354,"json":"https://www.erudio.com/trials/majestec-3-nct05083169.json","name":"MajesTEC-3","nct_id":"NCT05083169","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/majestec-3-nct05083169"},{"commentary_sources":352,"json":"https://www.erudio.com/trials/nct03924895.json","name":"NCT03924895","nct_id":"NCT03924895","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","url":"https://www.erudio.com/trials/nct03924895"},{"commentary_sources":347,"json":"https://www.erudio.com/trials/nct04784715.json","name":"NCT04784715","nct_id":"NCT04784715","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","url":"https://www.erudio.com/trials/nct04784715"},{"commentary_sources":344,"json":"https://www.erudio.com/trials/nct03734029.json","name":"NCT03734029","nct_id":"NCT03734029","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","url":"https://www.erudio.com/trials/nct03734029"},{"commentary_sources":334,"json":"https://www.erudio.com/trials/cartitude-1-nct03548207.json","name":"CARTITUDE-1","nct_id":"NCT03548207","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/cartitude-1-nct03548207"},{"commentary_sources":323,"json":"https://www.erudio.com/trials/ascent-04-nct05382286.json","name":"ASCENT-04","nct_id":"NCT05382286","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","url":"https://www.erudio.com/trials/ascent-04-nct05382286"},{"commentary_sources":305,"json":"https://www.erudio.com/trials/arasens-nct02799602.json","name":"ARASENS","nct_id":"NCT02799602","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","url":"https://www.erudio.com/trials/arasens-nct02799602"},{"commentary_sources":300,"json":"https://www.erudio.com/trials/karmma-3-nct03651128.json","name":"KarMMa-3","nct_id":"NCT03651128","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","url":"https://www.erudio.com/trials/karmma-3-nct03651128"},{"commentary_sources":300,"json":"https://www.erudio.com/trials/imvigor011-nct04660344.json","name":"IMvigor011","nct_id":"NCT04660344","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","url":"https://www.erudio.com/trials/imvigor011-nct04660344"},{"commentary_sources":297,"json":"https://www.erudio.com/trials/checkmate-274-nct02632409.json","name":"CheckMate 274","nct_id":"NCT02632409","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer","url":"https://www.erudio.com/trials/checkmate-274-nct02632409"},{"commentary_sources":297,"json":"https://www.erudio.com/trials/checkmate901-nct03036098.json","name":"CheckMate901","nct_id":"NCT03036098","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","url":"https://www.erudio.com/trials/checkmate901-nct03036098"},{"commentary_sources":297,"json":"https://www.erudio.com/trials/psmaddition-nct04720157.json","name":"PSMAddition","nct_id":"NCT04720157","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","url":"https://www.erudio.com/trials/psmaddition-nct04720157"},{"commentary_sources":286,"json":"https://www.erudio.com/trials/polarix-nct03274492.json","name":"POLARIX","nct_id":"NCT03274492","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","url":"https://www.erudio.com/trials/polarix-nct03274492"},{"commentary_sources":278,"json":"https://www.erudio.com/trials/ascent-03-nct05382299.json","name":"ASCENT-03","nct_id":"NCT05382299","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","url":"https://www.erudio.com/trials/ascent-03-nct05382299"},{"commentary_sources":276,"json":"https://www.erudio.com/trials/nct04656652.json","name":"NCT04656652","nct_id":"NCT04656652","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","url":"https://www.erudio.com/trials/nct04656652"},{"commentary_sources":263,"json":"https://www.erudio.com/trials/nadina-nct04949113.json","name":"NADINA","nct_id":"NCT04949113","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","url":"https://www.erudio.com/trials/nadina-nct04949113"},{"commentary_sources":253,"json":"https://www.erudio.com/trials/nct03740529.json","name":"NCT03740529","nct_id":"NCT03740529","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","url":"https://www.erudio.com/trials/nct03740529"},{"commentary_sources":250,"json":"https://www.erudio.com/trials/zuma-7-nct03391466.json","name":"ZUMA-7","nct_id":"NCT03391466","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","url":"https://www.erudio.com/trials/zuma-7-nct03391466"},{"commentary_sources":249,"json":"https://www.erudio.com/trials/capitello-291-nct04305496.json","name":"CAPItello-291","nct_id":"NCT04305496","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","url":"https://www.erudio.com/trials/capitello-291-nct04305496"},{"commentary_sources":243,"json":"https://www.erudio.com/trials/nct03937635.json","name":"NCT03937635","nct_id":"NCT03937635","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","url":"https://www.erudio.com/trials/nct03937635"},{"commentary_sources":238,"json":"https://www.erudio.com/trials/dellphi-304-nct05740566.json","name":"DeLLphi-304","nct_id":"NCT05740566","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","url":"https://www.erudio.com/trials/dellphi-304-nct05740566"},{"commentary_sources":236,"json":"https://www.erudio.com/trials/checkmate-8hw-nct04008030.json","name":"CheckMate 8HW","nct_id":"NCT04008030","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)","url":"https://www.erudio.com/trials/checkmate-8hw-nct04008030"},{"commentary_sources":235,"json":"https://www.erudio.com/trials/nct04622319.json","name":"NCT04622319","nct_id":"NCT04622319","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","url":"https://www.erudio.com/trials/nct04622319"},{"commentary_sources":234,"json":"https://www.erudio.com/trials/rasolute-302-nct06625320.json","name":"RASolute 302","nct_id":"NCT06625320","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","url":"https://www.erudio.com/trials/rasolute-302-nct06625320"},{"commentary_sources":228,"json":"https://www.erudio.com/trials/keynote-b15-nct04700124.json","name":"KEYNOTE-B15","nct_id":"NCT04700124","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","url":"https://www.erudio.com/trials/keynote-b15-nct04700124"},{"commentary_sources":225,"json":"https://www.erudio.com/trials/inavo120-nct04191499.json","name":"INAVO120","nct_id":"NCT04191499","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","url":"https://www.erudio.com/trials/inavo120-nct04191499"},{"commentary_sources":225,"json":"https://www.erudio.com/trials/postmonarch-nct05169567.json","name":"postMONARCH","nct_id":"NCT05169567","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","url":"https://www.erudio.com/trials/postmonarch-nct05169567"},{"commentary_sources":224,"json":"https://www.erudio.com/trials/nct05113251.json","name":"NCT05113251","nct_id":"NCT05113251","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","url":"https://www.erudio.com/trials/nct05113251"},{"commentary_sources":221,"json":"https://www.erudio.com/trials/cosmic-313-nct03937219.json","name":"COSMIC-313","nct_id":"NCT03937219","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","url":"https://www.erudio.com/trials/cosmic-313-nct03937219"},{"commentary_sources":221,"json":"https://www.erudio.com/trials/nct04566328.json","name":"NCT04566328","nct_id":"NCT04566328","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","url":"https://www.erudio.com/trials/nct04566328"},{"commentary_sources":219,"json":"https://www.erudio.com/trials/nct05104866.json","name":"NCT05104866","nct_id":"NCT05104866","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","url":"https://www.erudio.com/trials/nct05104866"},{"commentary_sources":215,"json":"https://www.erudio.com/trials/nct04821622.json","name":"NCT04821622","nct_id":"NCT04821622","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","url":"https://www.erudio.com/trials/nct04821622"},{"commentary_sources":214,"json":"https://www.erudio.com/trials/chaarted-nct00309985.json","name":"CHAARTED","nct_id":"NCT00309985","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer","url":"https://www.erudio.com/trials/chaarted-nct00309985"},{"commentary_sources":214,"json":"https://www.erudio.com/trials/nct03907488.json","name":"NCT03907488","nct_id":"NCT03907488","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","url":"https://www.erudio.com/trials/nct03907488"},{"commentary_sources":213,"json":"https://www.erudio.com/trials/nct02231749.json","name":"NCT02231749","nct_id":"NCT02231749","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)","url":"https://www.erudio.com/trials/nct02231749"},{"commentary_sources":210,"json":"https://www.erudio.com/trials/imroz-nct03319667.json","name":"IMROZ","nct_id":"NCT03319667","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","url":"https://www.erudio.com/trials/imroz-nct03319667"},{"commentary_sources":206,"json":"https://www.erudio.com/trials/neoadaura-nct04351555.json","name":"NeoADAURA","nct_id":"NCT04351555","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/neoadaura-nct04351555"},{"commentary_sources":201,"json":"https://www.erudio.com/trials/enzamet-nct02446405.json","name":"ENZAMET","nct_id":"NCT02446405","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","url":"https://www.erudio.com/trials/enzamet-nct02446405"},{"commentary_sources":201,"json":"https://www.erudio.com/trials/nct05374512.json","name":"NCT05374512","nct_id":"NCT05374512","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","url":"https://www.erudio.com/trials/nct05374512"},{"commentary_sources":196,"json":"https://www.erudio.com/trials/dpt02-nct04482309.json","name":"DPT02","nct_id":"NCT04482309","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","url":"https://www.erudio.com/trials/dpt02-nct04482309"},{"commentary_sources":193,"json":"https://www.erudio.com/trials/viktoria-1-nct05501886.json","name":"VIKTORIA-1","nct_id":"NCT05501886","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","url":"https://www.erudio.com/trials/viktoria-1-nct05501886"},{"commentary_sources":192,"json":"https://www.erudio.com/trials/checkmate-577-nct02743494.json","name":"CheckMate 577","nct_id":"NCT02743494","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer","url":"https://www.erudio.com/trials/checkmate-577-nct02743494"},{"commentary_sources":190,"json":"https://www.erudio.com/trials/nct02242942.json","name":"NCT02242942","nct_id":"NCT02242942","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia","url":"https://www.erudio.com/trials/nct02242942"},{"commentary_sources":190,"json":"https://www.erudio.com/trials/nct02563002.json","name":"NCT02563002","nct_id":"NCT02563002","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","url":"https://www.erudio.com/trials/nct02563002"},{"commentary_sources":187,"json":"https://www.erudio.com/trials/imforte-nct05091567.json","name":"IMforte","nct_id":"NCT05091567","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer","url":"https://www.erudio.com/trials/imforte-nct05091567"},{"commentary_sources":186,"json":"https://www.erudio.com/trials/imbrave150-nct03434379.json","name":"IMbrave150","nct_id":"NCT03434379","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma","url":"https://www.erudio.com/trials/imbrave150-nct03434379"},{"commentary_sources":186,"json":"https://www.erudio.com/trials/nct04987203.json","name":"NCT04987203","nct_id":"NCT04987203","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma","url":"https://www.erudio.com/trials/nct04987203"},{"commentary_sources":181,"json":"https://www.erudio.com/trials/aranote-nct04736199.json","name":"ARANOTE","nct_id":"NCT04736199","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","url":"https://www.erudio.com/trials/aranote-nct04736199"},{"commentary_sources":179,"json":"https://www.erudio.com/trials/tropics-02-nct03901339.json","name":"TROPiCS-02","nct_id":"NCT03901339","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","url":"https://www.erudio.com/trials/tropics-02-nct03901339"},{"commentary_sources":179,"json":"https://www.erudio.com/trials/cll17-nct04608318.json","name":"CLL17","nct_id":"NCT04608318","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)","url":"https://www.erudio.com/trials/cll17-nct04608318"},{"commentary_sources":178,"json":"https://www.erudio.com/trials/checkmate-9er-nct03141177.json","name":"CheckMate 9ER","nct_id":"NCT03141177","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","url":"https://www.erudio.com/trials/checkmate-9er-nct03141177"},{"commentary_sources":175,"json":"https://www.erudio.com/trials/mirasol-nct04209855.json","name":"MIRASOL","nct_id":"NCT04209855","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","url":"https://www.erudio.com/trials/mirasol-nct04209855"},{"commentary_sources":175,"json":"https://www.erudio.com/trials/contact-03-nct04338269.json","name":"CONTACT-03","nct_id":"NCT04338269","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","url":"https://www.erudio.com/trials/contact-03-nct04338269"},{"commentary_sources":167,"json":"https://www.erudio.com/trials/flaura-nct02296125.json","name":"FLAURA","nct_id":"NCT02296125","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/flaura-nct02296125"},{"commentary_sources":161,"json":"https://www.erudio.com/trials/her2climb-nct02614794.json","name":"HER2CLIMB","nct_id":"NCT02614794","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer","url":"https://www.erudio.com/trials/her2climb-nct02614794"},{"commentary_sources":160,"json":"https://www.erudio.com/trials/impower133-nct02763579.json","name":"IMpower133","nct_id":"NCT02763579","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)","url":"https://www.erudio.com/trials/impower133-nct02763579"},{"commentary_sources":157,"json":"https://www.erudio.com/trials/duo-e-nct04269200.json","name":"DUO-E","nct_id":"NCT04269200","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","url":"https://www.erudio.com/trials/duo-e-nct04269200"},{"commentary_sources":157,"json":"https://www.erudio.com/trials/psmafore-nct04689828.json","name":"PSMAfore","nct_id":"NCT04689828","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","url":"https://www.erudio.com/trials/psmafore-nct04689828"},{"commentary_sources":156,"json":"https://www.erudio.com/trials/imbrave050-nct04102098.json","name":"IMbrave050","nct_id":"NCT04102098","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","url":"https://www.erudio.com/trials/imbrave050-nct04102098"},{"commentary_sources":154,"json":"https://www.erudio.com/trials/capitello-281-nct04493853.json","name":"CAPItello-281","nct_id":"NCT04493853","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","url":"https://www.erudio.com/trials/capitello-281-nct04493853"},{"commentary_sources":153,"json":"https://www.erudio.com/trials/nct02603432.json","name":"NCT02603432","nct_id":"NCT02603432","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)","url":"https://www.erudio.com/trials/nct02603432"},{"commentary_sources":152,"json":"https://www.erudio.com/trials/begonia-nct03742102.json","name":"BEGONIA","nct_id":"NCT03742102","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","url":"https://www.erudio.com/trials/begonia-nct03742102"},{"commentary_sources":151,"json":"https://www.erudio.com/trials/monarch-3-nct02246621.json","name":"MONARCH 3","nct_id":"NCT02246621","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer","url":"https://www.erudio.com/trials/monarch-3-nct02246621"},{"commentary_sources":151,"json":"https://www.erudio.com/trials/tapur-nct02693535.json","name":"TAPUR","nct_id":"NCT02693535","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","url":"https://www.erudio.com/trials/tapur-nct02693535"},{"commentary_sources":150,"json":"https://www.erudio.com/trials/veritac-2-nct05654623.json","name":"VERITAC-2","nct_id":"NCT05654623","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","url":"https://www.erudio.com/trials/veritac-2-nct05654623"},{"commentary_sources":149,"json":"https://www.erudio.com/trials/ev-103-nct03288545.json","name":"EV-103","nct_id":"NCT03288545","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","url":"https://www.erudio.com/trials/ev-103-nct03288545"},{"commentary_sources":149,"json":"https://www.erudio.com/trials/nct03529110.json","name":"NCT03529110","nct_id":"NCT03529110","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","url":"https://www.erudio.com/trials/nct03529110"},{"commentary_sources":149,"json":"https://www.erudio.com/trials/nct04484142.json","name":"NCT04484142","nct_id":"NCT04484142","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)","url":"https://www.erudio.com/trials/nct04484142"},{"commentary_sources":148,"json":"https://www.erudio.com/trials/majestec-9-nct05572515.json","name":"MajesTEC-9","nct_id":"NCT05572515","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/majestec-9-nct05572515"},{"commentary_sources":146,"json":"https://www.erudio.com/trials/her2climb-05-nct05132582.json","name":"HER2CLIMB-05","nct_id":"NCT05132582","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","url":"https://www.erudio.com/trials/her2climb-05-nct05132582"},{"commentary_sources":144,"json":"https://www.erudio.com/trials/tailorx-nct00310180.json","name":"TAILORx","nct_id":"NCT00310180","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","url":"https://www.erudio.com/trials/tailorx-nct00310180"},{"commentary_sources":142,"json":"https://www.erudio.com/trials/gaia-nct02950051.json","name":"GAIA","nct_id":"NCT02950051","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation","url":"https://www.erudio.com/trials/gaia-nct02950051"},{"commentary_sources":141,"json":"https://www.erudio.com/trials/netter-2-nct03972488.json","name":"NETTER-2","nct_id":"NCT03972488","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","url":"https://www.erudio.com/trials/netter-2-nct03972488"},{"commentary_sources":140,"json":"https://www.erudio.com/trials/quantum-first-nct02668653.json","name":"QuANTUM-First","nct_id":"NCT02668653","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","url":"https://www.erudio.com/trials/quantum-first-nct02668653"},{"commentary_sources":138,"json":"https://www.erudio.com/trials/drammatic-nct04071457.json","name":"DRAMMATIC","nct_id":"NCT04071457","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration","url":"https://www.erudio.com/trials/drammatic-nct04071457"},{"commentary_sources":138,"json":"https://www.erudio.com/trials/nct05239728.json","name":"NCT05239728","nct_id":"NCT05239728","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)","url":"https://www.erudio.com/trials/nct05239728"},{"commentary_sources":137,"json":"https://www.erudio.com/trials/nct04704934.json","name":"NCT04704934","nct_id":"NCT04704934","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","url":"https://www.erudio.com/trials/nct04704934"},{"commentary_sources":136,"json":"https://www.erudio.com/trials/murano-nct02005471.json","name":"MURANO","nct_id":"NCT02005471","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","url":"https://www.erudio.com/trials/murano-nct02005471"},{"commentary_sources":136,"json":"https://www.erudio.com/trials/serena-2-nct04214288.json","name":"SERENA-2","nct_id":"NCT04214288","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","url":"https://www.erudio.com/trials/serena-2-nct04214288"},{"commentary_sources":134,"json":"https://www.erudio.com/trials/nct03725059.json","name":"NCT03725059","nct_id":"NCT03725059","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","url":"https://www.erudio.com/trials/nct03725059"},{"commentary_sources":131,"json":"https://www.erudio.com/trials/elevatetn-nct02475681.json","name":"ElevateTN","nct_id":"NCT02475681","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","url":"https://www.erudio.com/trials/elevatetn-nct02475681"},{"commentary_sources":130,"json":"https://www.erudio.com/trials/nct02819518.json","name":"NCT02819518","nct_id":"NCT02819518","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)","url":"https://www.erudio.com/trials/nct02819518"},{"commentary_sources":130,"json":"https://www.erudio.com/trials/fresco-2-nct04322539.json","name":"FRESCO-2","nct_id":"NCT04322539","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer","url":"https://www.erudio.com/trials/fresco-2-nct04322539"},{"commentary_sources":129,"json":"https://www.erudio.com/trials/herizon-gea-01-nct05152147.json","name":"HERIZON-GEA-01","nct_id":"NCT05152147","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","url":"https://www.erudio.com/trials/herizon-gea-01-nct05152147"},{"commentary_sources":128,"json":"https://www.erudio.com/trials/solar-1-nct02437318.json","name":"SOLAR-1","nct_id":"NCT02437318","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.","url":"https://www.erudio.com/trials/solar-1-nct02437318"},{"commentary_sources":127,"json":"https://www.erudio.com/trials/transmet-nct02597348.json","name":"TRANSMET","nct_id":"NCT02597348","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy","url":"https://www.erudio.com/trials/transmet-nct02597348"},{"commentary_sources":127,"json":"https://www.erudio.com/trials/destiny-b12-nct04739761.json","name":"DESTINY-B12","nct_id":"NCT04739761","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","url":"https://www.erudio.com/trials/destiny-b12-nct04739761"},{"commentary_sources":125,"json":"https://www.erudio.com/trials/imvigor010-nct02450331.json","name":"IMvigor010","nct_id":"NCT02450331","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection","url":"https://www.erudio.com/trials/imvigor010-nct02450331"},{"commentary_sources":125,"json":"https://www.erudio.com/trials/nct04303780.json","name":"NCT04303780","nct_id":"NCT04303780","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).","url":"https://www.erudio.com/trials/nct04303780"},{"commentary_sources":124,"json":"https://www.erudio.com/trials/destiny-lung01-nct03505710.json","name":"DESTINY-Lung01","nct_id":"NCT03505710","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/destiny-lung01-nct03505710"},{"commentary_sources":124,"json":"https://www.erudio.com/trials/libretto-432-nct04819100.json","name":"LIBRETTO-432","nct_id":"NCT04819100","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/libretto-432-nct04819100"},{"commentary_sources":122,"json":"https://www.erudio.com/trials/pada-1-nct03079011.json","name":"PADA-1","nct_id":"NCT03079011","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","url":"https://www.erudio.com/trials/pada-1-nct03079011"},{"commentary_sources":121,"json":"https://www.erudio.com/trials/nct04246177.json","name":"NCT04246177","nct_id":"NCT04246177","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","url":"https://www.erudio.com/trials/nct04246177"},{"commentary_sources":119,"json":"https://www.erudio.com/trials/contact-02-nct04446117.json","name":"CONTACT-02","nct_id":"NCT04446117","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","url":"https://www.erudio.com/trials/contact-02-nct04446117"},{"commentary_sources":118,"json":"https://www.erudio.com/trials/nct01730937.json","name":"NCT01730937","nct_id":"NCT01730937","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer","url":"https://www.erudio.com/trials/nct01730937"},{"commentary_sources":118,"json":"https://www.erudio.com/trials/checkmate-9dw-nct04039607.json","name":"CheckMate 9DW","nct_id":"NCT04039607","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","url":"https://www.erudio.com/trials/checkmate-9dw-nct04039607"},{"commentary_sources":118,"json":"https://www.erudio.com/trials/sunrise-4-nct04919512.json","name":"SunRISe-4","nct_id":"NCT04919512","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder","url":"https://www.erudio.com/trials/sunrise-4-nct04919512"},{"commentary_sources":116,"json":"https://www.erudio.com/trials/circulate-us-nct05174169.json","name":"CIRCULATE-US","nct_id":"NCT05174169","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","url":"https://www.erudio.com/trials/circulate-us-nct05174169"},{"commentary_sources":114,"json":"https://www.erudio.com/trials/impower150-nct02366143.json","name":"IMpower150","nct_id":"NCT02366143","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/impower150-nct02366143"},{"commentary_sources":114,"json":"https://www.erudio.com/trials/triton3-nct02975934.json","name":"TRITON3","nct_id":"NCT02975934","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","url":"https://www.erudio.com/trials/triton3-nct02975934"},{"commentary_sources":114,"json":"https://www.erudio.com/trials/nct04221945.json","name":"NCT04221945","nct_id":"NCT04221945","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","url":"https://www.erudio.com/trials/nct04221945"},{"commentary_sources":113,"json":"https://www.erudio.com/trials/enzarad-nct02446444.json","name":"ENZARAD","nct_id":"NCT02446444","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer","url":"https://www.erudio.com/trials/enzarad-nct02446444"},{"commentary_sources":112,"json":"https://www.erudio.com/trials/nct03137771.json","name":"NCT03137771","nct_id":"NCT03137771","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct03137771"},{"commentary_sources":111,"json":"https://www.erudio.com/trials/sabr-comet-nct01446744.json","name":"SABR-COMET","nct_id":"NCT01446744","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)","url":"https://www.erudio.com/trials/sabr-comet-nct01446744"},{"commentary_sources":111,"json":"https://www.erudio.com/trials/checkmate-9la-nct03215706.json","name":"CheckMate 9LA","nct_id":"NCT03215706","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC","url":"https://www.erudio.com/trials/checkmate-9la-nct03215706"},{"commentary_sources":111,"json":"https://www.erudio.com/trials/manifest-2-nct04603495.json","name":"MANIFEST-2","nct_id":"NCT04603495","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","url":"https://www.erudio.com/trials/manifest-2-nct04603495"},{"commentary_sources":111,"json":"https://www.erudio.com/trials/dellphi-301-nct05060016.json","name":"DeLLphi-301","nct_id":"NCT05060016","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","url":"https://www.erudio.com/trials/dellphi-301-nct05060016"},{"commentary_sources":110,"json":"https://www.erudio.com/trials/cartitude-6-nct05257083.json","name":"CARTITUDE-6","nct_id":"NCT05257083","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","url":"https://www.erudio.com/trials/cartitude-6-nct05257083"},{"commentary_sources":109,"json":"https://www.erudio.com/trials/right-choice-nct03839823.json","name":"RIGHT Choice","nct_id":"NCT03839823","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","url":"https://www.erudio.com/trials/right-choice-nct03839823"},{"commentary_sources":109,"json":"https://www.erudio.com/trials/herizon-btc-01-nct04466891.json","name":"HERIZON-BTC-01","nct_id":"NCT04466891","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers","url":"https://www.erudio.com/trials/herizon-btc-01-nct04466891"},{"commentary_sources":108,"json":"https://www.erudio.com/trials/zuma-1-nct02348216.json","name":"ZUMA-1","nct_id":"NCT02348216","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","url":"https://www.erudio.com/trials/zuma-1-nct02348216"},{"commentary_sources":108,"json":"https://www.erudio.com/trials/imvigor130-nct02807636.json","name":"IMvigor130","nct_id":"NCT02807636","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma","url":"https://www.erudio.com/trials/imvigor130-nct02807636"},{"commentary_sources":105,"json":"https://www.erudio.com/trials/nct03698019.json","name":"NCT03698019","nct_id":"NCT03698019","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","url":"https://www.erudio.com/trials/nct03698019"},{"commentary_sources":104,"json":"https://www.erudio.com/trials/nct03474107.json","name":"NCT03474107","nct_id":"NCT03474107","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)","url":"https://www.erudio.com/trials/nct03474107"},{"commentary_sources":102,"json":"https://www.erudio.com/trials/checkmate-227-nct02477826.json","name":"CheckMate 227","nct_id":"NCT02477826","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/checkmate-227-nct02477826"},{"commentary_sources":102,"json":"https://www.erudio.com/trials/therap-nct03392428.json","name":"TheraP","nct_id":"NCT03392428","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer","url":"https://www.erudio.com/trials/therap-nct03392428"},{"commentary_sources":102,"json":"https://www.erudio.com/trials/enza-p-nct04419402.json","name":"ENZA-p","nct_id":"NCT04419402","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer","url":"https://www.erudio.com/trials/enza-p-nct04419402"},{"commentary_sources":102,"json":"https://www.erudio.com/trials/destiny-lung02-nct04644237.json","name":"DESTINY-LUNG02","nct_id":"NCT04644237","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/destiny-lung02-nct04644237"},{"commentary_sources":102,"json":"https://www.erudio.com/trials/successor-2-nct05552976.json","name":"SUCCESSOR-2","nct_id":"NCT05552976","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","url":"https://www.erudio.com/trials/successor-2-nct05552976"},{"commentary_sources":101,"json":"https://www.erudio.com/trials/pearls-nct02504372.json","name":"PEARLS","nct_id":"NCT02504372","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","url":"https://www.erudio.com/trials/pearls-nct02504372"},{"commentary_sources":101,"json":"https://www.erudio.com/trials/zuma-5-nct03105336.json","name":"ZUMA-5","nct_id":"NCT03105336","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma","url":"https://www.erudio.com/trials/zuma-5-nct03105336"},{"commentary_sources":101,"json":"https://www.erudio.com/trials/evoke-01-nct05089734.json","name":"EVOKE-01","nct_id":"NCT05089734","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/evoke-01-nct05089734"},{"commentary_sources":100,"json":"https://www.erudio.com/trials/nct02853331.json","name":"NCT02853331","nct_id":"NCT02853331","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)","url":"https://www.erudio.com/trials/nct02853331"},{"commentary_sources":98,"json":"https://www.erudio.com/trials/nct01844505.json","name":"NCT01844505","nct_id":"NCT01844505","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)","url":"https://www.erudio.com/trials/nct01844505"},{"commentary_sources":98,"json":"https://www.erudio.com/trials/immotion010-nct03024996.json","name":"IMmotion010","nct_id":"NCT03024996","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy","url":"https://www.erudio.com/trials/immotion010-nct03024996"},{"commentary_sources":97,"json":"https://www.erudio.com/trials/ikema-nct03275285.json","name":"IKEMA","nct_id":"NCT03275285","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","url":"https://www.erudio.com/trials/ikema-nct03275285"},{"commentary_sources":97,"json":"https://www.erudio.com/trials/nct05048797.json","name":"NCT05048797","nct_id":"NCT05048797","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","url":"https://www.erudio.com/trials/nct05048797"},{"commentary_sources":96,"json":"https://www.erudio.com/trials/krystal-12-nct04685135.json","name":"KRYSTAL-12","nct_id":"NCT04685135","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","url":"https://www.erudio.com/trials/krystal-12-nct04685135"},{"commentary_sources":95,"json":"https://www.erudio.com/trials/chrysalis-2-nct04077463.json","name":"Chrysalis-2","nct_id":"NCT04077463","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/chrysalis-2-nct04077463"},{"commentary_sources":95,"json":"https://www.erudio.com/trials/frontmind-nct04824092.json","name":"frontMIND","nct_id":"NCT04824092","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","url":"https://www.erudio.com/trials/frontmind-nct04824092"},{"commentary_sources":94,"json":"https://www.erudio.com/trials/augment-101-nct04065399.json","name":"AUGMENT-101","nct_id":"NCT04065399","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","url":"https://www.erudio.com/trials/augment-101-nct04065399"},{"commentary_sources":93,"json":"https://www.erudio.com/trials/checkmate-7fl-nct04109066.json","name":"CheckMate 7FL","nct_id":"NCT04109066","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","url":"https://www.erudio.com/trials/checkmate-7fl-nct04109066"},{"commentary_sources":92,"json":"https://www.erudio.com/trials/topgear-nct01924819.json","name":"TOPGEAR","nct_id":"NCT01924819","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","url":"https://www.erudio.com/trials/topgear-nct01924819"},{"commentary_sources":91,"json":"https://www.erudio.com/trials/epcore-fl-1-nct05409066.json","name":"EPCORE FL-1","nct_id":"NCT05409066","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma","url":"https://www.erudio.com/trials/epcore-fl-1-nct05409066"},{"commentary_sources":91,"json":"https://www.erudio.com/trials/stellar-303-nct05425940.json","name":"STELLAR-303","nct_id":"NCT05425940","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","url":"https://www.erudio.com/trials/stellar-303-nct05425940"},{"commentary_sources":90,"json":"https://www.erudio.com/trials/serena-4-nct04711252.json","name":"SERENA-4","nct_id":"NCT04711252","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","url":"https://www.erudio.com/trials/serena-4-nct04711252"},{"commentary_sources":90,"json":"https://www.erudio.com/trials/destiny-crc02-nct04744831.json","name":"DESTINY-CRC02","nct_id":"NCT04744831","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","url":"https://www.erudio.com/trials/destiny-crc02-nct04744831"},{"commentary_sources":89,"json":"https://www.erudio.com/trials/nivopostop-nct03576417.json","name":"NIVOPOSTOP","nct_id":"NCT03576417","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck","url":"https://www.erudio.com/trials/nivopostop-nct03576417"},{"commentary_sources":89,"json":"https://www.erudio.com/trials/bellini-nct03815890.json","name":"BELLINI","nct_id":"NCT03815890","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO","url":"https://www.erudio.com/trials/bellini-nct03815890"},{"commentary_sources":88,"json":"https://www.erudio.com/trials/sympatico-nct03112174.json","name":"SYMPATICO","nct_id":"NCT03112174","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)","url":"https://www.erudio.com/trials/sympatico-nct03112174"},{"commentary_sources":88,"json":"https://www.erudio.com/trials/libretto-431-nct04194944.json","name":"LIBRETTO-431","nct_id":"NCT04194944","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/libretto-431-nct04194944"},{"commentary_sources":88,"json":"https://www.erudio.com/trials/cartitude-5-nct04923893.json","name":"CARTITUDE-5","nct_id":"NCT04923893","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","url":"https://www.erudio.com/trials/cartitude-5-nct04923893"},{"commentary_sources":85,"json":"https://www.erudio.com/trials/iskia-nct04483739.json","name":"IsKia","nct_id":"NCT04483739","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)","url":"https://www.erudio.com/trials/iskia-nct04483739"},{"commentary_sources":85,"json":"https://www.erudio.com/trials/nct05257408.json","name":"NCT05257408","nct_id":"NCT05257408","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","url":"https://www.erudio.com/trials/nct05257408"},{"commentary_sources":85,"json":"https://www.erudio.com/trials/mdt-bridge-nct05925530.json","name":"MDT-BRIDGE","nct_id":"NCT05925530","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","url":"https://www.erudio.com/trials/mdt-bridge-nct05925530"},{"commentary_sources":84,"json":"https://www.erudio.com/trials/nct01216644.json","name":"NCT01216644","nct_id":"NCT01216644","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer","url":"https://www.erudio.com/trials/nct01216644"},{"commentary_sources":83,"json":"https://www.erudio.com/trials/nct01726452.json","name":"NCT01726452","nct_id":"NCT01726452","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","url":"https://www.erudio.com/trials/nct01726452"},{"commentary_sources":83,"json":"https://www.erudio.com/trials/nct04649359.json","name":"NCT04649359","nct_id":"NCT04649359","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb","url":"https://www.erudio.com/trials/nct04649359"},{"commentary_sources":82,"json":"https://www.erudio.com/trials/alban-nct03799835.json","name":"ALBAN","nct_id":"NCT03799835","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients","url":"https://www.erudio.com/trials/alban-nct03799835"},{"commentary_sources":82,"json":"https://www.erudio.com/trials/neostar-nct04230109.json","name":"NeoSTAR","nct_id":"NCT04230109","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Sacituzumab Govitecan In TNBC","url":"https://www.erudio.com/trials/neostar-nct04230109"},{"commentary_sources":81,"json":"https://www.erudio.com/trials/penelope-b-nct01864746.json","name":"PENELOPE-B","nct_id":"NCT01864746","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery","url":"https://www.erudio.com/trials/penelope-b-nct01864746"},{"commentary_sources":81,"json":"https://www.erudio.com/trials/checkmate-914-nct03138512.json","name":"CheckMate 914","nct_id":"NCT03138512","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney","url":"https://www.erudio.com/trials/checkmate-914-nct03138512"},{"commentary_sources":81,"json":"https://www.erudio.com/trials/redirectt-1-nct04586426.json","name":"RedirecTT-1","nct_id":"NCT04586426","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/redirectt-1-nct04586426"},{"commentary_sources":79,"json":"https://www.erudio.com/trials/nct02628067.json","name":"NCT02628067","nct_id":"NCT02628067","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","url":"https://www.erudio.com/trials/nct02628067"},{"commentary_sources":78,"json":"https://www.erudio.com/trials/duo-o-nct03737643.json","name":"DUO-O","nct_id":"NCT03737643","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","url":"https://www.erudio.com/trials/duo-o-nct03737643"},{"commentary_sources":78,"json":"https://www.erudio.com/trials/dg-03-nct04379596.json","name":"DG-03","nct_id":"NCT04379596","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","url":"https://www.erudio.com/trials/dg-03-nct04379596"},{"commentary_sources":77,"json":"https://www.erudio.com/trials/simplify-1-nct01969838.json","name":"Simplify 1","nct_id":"NCT01969838","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis","url":"https://www.erudio.com/trials/simplify-1-nct01969838"},{"commentary_sources":77,"json":"https://www.erudio.com/trials/pop-rt-nct02302105.json","name":"POP-RT","nct_id":"NCT02302105","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer","url":"https://www.erudio.com/trials/pop-rt-nct02302105"},{"commentary_sources":77,"json":"https://www.erudio.com/trials/nct02684006.json","name":"NCT02684006","nct_id":"NCT02684006","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","url":"https://www.erudio.com/trials/nct02684006"},{"commentary_sources":77,"json":"https://www.erudio.com/trials/relativity-047-nct03470922.json","name":"RELATIVITY-047","nct_id":"NCT03470922","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma","url":"https://www.erudio.com/trials/relativity-047-nct03470922"},{"commentary_sources":77,"json":"https://www.erudio.com/trials/tropics-04-nct04527991.json","name":"TROPiCS-04","nct_id":"NCT04527991","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","url":"https://www.erudio.com/trials/tropics-04-nct04527991"},{"commentary_sources":75,"json":"https://www.erudio.com/trials/bruin-cll-313-nct05023980.json","name":"BRUIN-CLL-313","nct_id":"NCT05023980","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","url":"https://www.erudio.com/trials/bruin-cll-313-nct05023980"},{"commentary_sources":74,"json":"https://www.erudio.com/trials/sunmo-nct05171647.json","name":"SUNMO","nct_id":"NCT05171647","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","url":"https://www.erudio.com/trials/sunmo-nct05171647"},{"commentary_sources":74,"json":"https://www.erudio.com/trials/gloriosa-nct05445778.json","name":"GLORIOSA","nct_id":"NCT05445778","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","url":"https://www.erudio.com/trials/gloriosa-nct05445778"},{"commentary_sources":74,"json":"https://www.erudio.com/trials/hd10-dsmmxx-nct05695508.json","name":"HD10/DSMMXX","nct_id":"NCT05695508","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","url":"https://www.erudio.com/trials/hd10-dsmmxx-nct05695508"},{"commentary_sources":74,"json":"https://www.erudio.com/trials/ascent-07-nct05840211.json","name":"ASCENT-07","nct_id":"NCT05840211","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","url":"https://www.erudio.com/trials/ascent-07-nct05840211"},{"commentary_sources":73,"json":"https://www.erudio.com/trials/pout-nct01993979.json","name":"POUT","nct_id":"NCT01993979","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)","url":"https://www.erudio.com/trials/pout-nct01993979"},{"commentary_sources":73,"json":"https://www.erudio.com/trials/nct03377491.json","name":"NCT03377491","nct_id":"NCT03377491","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)","url":"https://www.erudio.com/trials/nct03377491"},{"commentary_sources":73,"json":"https://www.erudio.com/trials/nct05116189.json","name":"NCT05116189","nct_id":"NCT05116189","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","url":"https://www.erudio.com/trials/nct05116189"},{"commentary_sources":72,"json":"https://www.erudio.com/trials/oriole-nct02680587.json","name":"ORIOLE","nct_id":"NCT02680587","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Stereotactic Body Radiation for Prostate Oligometastases","url":"https://www.erudio.com/trials/oriole-nct02680587"},{"commentary_sources":72,"json":"https://www.erudio.com/trials/nct03331198.json","name":"NCT03331198","nct_id":"NCT03331198","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","url":"https://www.erudio.com/trials/nct03331198"},{"commentary_sources":72,"json":"https://www.erudio.com/trials/linker-mm1-nct03761108.json","name":"LINKER-MM1","nct_id":"NCT03761108","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/linker-mm1-nct03761108"},{"commentary_sources":72,"json":"https://www.erudio.com/trials/dellphi-305-nct06211036.json","name":"DeLLphi-305","nct_id":"NCT06211036","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab","url":"https://www.erudio.com/trials/dellphi-305-nct06211036"},{"commentary_sources":71,"json":"https://www.erudio.com/trials/nct00098475.json","name":"NCT00098475","nct_id":"NCT00098475","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","url":"https://www.erudio.com/trials/nct00098475"},{"commentary_sources":70,"json":"https://www.erudio.com/trials/insema-nct02466737.json","name":"INSEMA","nct_id":"NCT02466737","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery","url":"https://www.erudio.com/trials/insema-nct02466737"},{"commentary_sources":70,"json":"https://www.erudio.com/trials/monumental-3-nct05455320.json","name":"MonumenTAL-3","nct_id":"NCT05455320","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment","url":"https://www.erudio.com/trials/monumental-3-nct05455320"},{"commentary_sources":69,"json":"https://www.erudio.com/trials/monarch-2-nct02107703.json","name":"MONARCH 2","nct_id":"NCT02107703","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","url":"https://www.erudio.com/trials/monarch-2-nct02107703"},{"commentary_sources":69,"json":"https://www.erudio.com/trials/fastrack-ii-nct02613819.json","name":"FASTRACK II","nct_id":"NCT02613819","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney","url":"https://www.erudio.com/trials/fastrack-ii-nct02613819"},{"commentary_sources":69,"json":"https://www.erudio.com/trials/lap100-nct06958328.json","name":"LAP100","nct_id":"NCT06958328","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","url":"https://www.erudio.com/trials/lap100-nct06958328"},{"commentary_sources":68,"json":"https://www.erudio.com/trials/aphinity-nct01358877.json","name":"APHINITY","nct_id":"NCT01358877","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","url":"https://www.erudio.com/trials/aphinity-nct01358877"},{"commentary_sources":68,"json":"https://www.erudio.com/trials/pure-01-nct02736266.json","name":"PURE-01","nct_id":"NCT02736266","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma","url":"https://www.erudio.com/trials/pure-01-nct02736266"},{"commentary_sources":68,"json":"https://www.erudio.com/trials/stampede2-nct06320067.json","name":"STAMPEDE2","nct_id":"NCT06320067","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","url":"https://www.erudio.com/trials/stampede2-nct06320067"},{"commentary_sources":67,"json":"https://www.erudio.com/trials/partiqol-nct01617161.json","name":"PARTIQoL","nct_id":"NCT01617161","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer","url":"https://www.erudio.com/trials/partiqol-nct01617161"},{"commentary_sources":67,"json":"https://www.erudio.com/trials/cll12-nct02863718.json","name":"CLL12","nct_id":"NCT02863718","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression","url":"https://www.erudio.com/trials/cll12-nct02863718"},{"commentary_sources":67,"json":"https://www.erudio.com/trials/a-brave-nct02926196.json","name":"A-Brave","nct_id":"NCT02926196","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab","url":"https://www.erudio.com/trials/a-brave-nct02926196"},{"commentary_sources":67,"json":"https://www.erudio.com/trials/nct03975647.json","name":"NCT03975647","nct_id":"NCT03975647","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","url":"https://www.erudio.com/trials/nct03975647"},{"commentary_sources":67,"json":"https://www.erudio.com/trials/neocoast-2-nct05061550.json","name":"NeoCOAST-2","nct_id":"NCT05061550","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/neocoast-2-nct05061550"},{"commentary_sources":66,"json":"https://www.erudio.com/trials/nct02761057.json","name":"NCT02761057","nct_id":"NCT02761057","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","url":"https://www.erudio.com/trials/nct02761057"},{"commentary_sources":65,"json":"https://www.erudio.com/trials/olympiad-nct02000622.json","name":"OlympiAD","nct_id":"NCT02000622","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","url":"https://www.erudio.com/trials/olympiad-nct02000622"},{"commentary_sources":64,"json":"https://www.erudio.com/trials/nct03914612.json","name":"NCT03914612","nct_id":"NCT03914612","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","url":"https://www.erudio.com/trials/nct03914612"},{"commentary_sources":64,"json":"https://www.erudio.com/trials/nct04526691.json","name":"NCT04526691","nct_id":"NCT04526691","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","url":"https://www.erudio.com/trials/nct04526691"},{"commentary_sources":64,"json":"https://www.erudio.com/trials/nct04619004.json","name":"NCT04619004","nct_id":"NCT04619004","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct04619004"},{"commentary_sources":63,"json":"https://www.erudio.com/trials/nct00533949.json","name":"NCT00533949","nct_id":"NCT00533949","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","url":"https://www.erudio.com/trials/nct00533949"},{"commentary_sources":63,"json":"https://www.erudio.com/trials/nct03248492.json","name":"NCT03248492","nct_id":"NCT03248492","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)","url":"https://www.erudio.com/trials/nct03248492"},{"commentary_sources":63,"json":"https://www.erudio.com/trials/zuma-23-nct05605899.json","name":"ZUMA-23","nct_id":"NCT05605899","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","url":"https://www.erudio.com/trials/zuma-23-nct05605899"},{"commentary_sources":62,"json":"https://www.erudio.com/trials/bruin-cll-321-nct04666038.json","name":"BRUIN CLL-321","nct_id":"NCT04666038","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","url":"https://www.erudio.com/trials/bruin-cll-321-nct04666038"},{"commentary_sources":61,"json":"https://www.erudio.com/trials/ilustro-nct03505320.json","name":"ILUSTRO","nct_id":"NCT03505320","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","url":"https://www.erudio.com/trials/ilustro-nct03505320"},{"commentary_sources":61,"json":"https://www.erudio.com/trials/nct03635567.json","name":"NCT03635567","nct_id":"NCT03635567","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","url":"https://www.erudio.com/trials/nct03635567"},{"commentary_sources":60,"json":"https://www.erudio.com/trials/netter-1-nct01578239.json","name":"NETTER-1","nct_id":"NCT01578239","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","url":"https://www.erudio.com/trials/netter-1-nct01578239"},{"commentary_sources":60,"json":"https://www.erudio.com/trials/phergain-nct03161353.json","name":"PHERGain","nct_id":"NCT03161353","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","url":"https://www.erudio.com/trials/phergain-nct03161353"},{"commentary_sources":60,"json":"https://www.erudio.com/trials/cartitude-2-nct04133636.json","name":"CARTITUDE-2","nct_id":"NCT04133636","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","url":"https://www.erudio.com/trials/cartitude-2-nct04133636"},{"commentary_sources":60,"json":"https://www.erudio.com/trials/nct05411081.json","name":"NCT05411081","nct_id":"NCT05411081","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial","url":"https://www.erudio.com/trials/nct05411081"},{"commentary_sources":60,"json":"https://www.erudio.com/trials/stellar-304-nct05678673.json","name":"STELLAR-304","nct_id":"NCT05678673","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma","url":"https://www.erudio.com/trials/stellar-304-nct05678673"},{"commentary_sources":59,"json":"https://www.erudio.com/trials/portec-3-nct00411138.json","name":"PORTEC-3","nct_id":"NCT00411138","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer","url":"https://www.erudio.com/trials/portec-3-nct00411138"},{"commentary_sources":59,"json":"https://www.erudio.com/trials/nct04014075.json","name":"NCT04014075","nct_id":"NCT04014075","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)","url":"https://www.erudio.com/trials/nct04014075"},{"commentary_sources":59,"json":"https://www.erudio.com/trials/iraklia-nct05405166.json","name":"IRAKLIA","nct_id":"NCT05405166","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","url":"https://www.erudio.com/trials/iraklia-nct05405166"},{"commentary_sources":59,"json":"https://www.erudio.com/trials/cambria-2-nct05952557.json","name":"CAMBRIA-2","nct_id":"NCT05952557","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","url":"https://www.erudio.com/trials/cambria-2-nct05952557"},{"commentary_sources":58,"json":"https://www.erudio.com/trials/nct03713593.json","name":"NCT03713593","nct_id":"NCT03713593","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)","url":"https://www.erudio.com/trials/nct03713593"},{"commentary_sources":57,"json":"https://www.erudio.com/trials/libretto-001-nct03157128.json","name":"LIBRETTO-001","nct_id":"NCT03157128","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)","url":"https://www.erudio.com/trials/libretto-001-nct03157128"},{"commentary_sources":57,"json":"https://www.erudio.com/trials/polargo-nct04182204.json","name":"POLARGO","nct_id":"NCT04182204","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","url":"https://www.erudio.com/trials/polargo-nct04182204"},{"commentary_sources":57,"json":"https://www.erudio.com/trials/bond-003-nct04452591.json","name":"BOND-003","nct_id":"NCT04452591","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","url":"https://www.erudio.com/trials/bond-003-nct04452591"},{"commentary_sources":56,"json":"https://www.erudio.com/trials/nct02003222.json","name":"NCT02003222","nct_id":"NCT02003222","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","url":"https://www.erudio.com/trials/nct02003222"},{"commentary_sources":56,"json":"https://www.erudio.com/trials/nct03811002.json","name":"NCT03811002","nct_id":"NCT03811002","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","url":"https://www.erudio.com/trials/nct03811002"},{"commentary_sources":55,"json":"https://www.erudio.com/trials/lung-art-nct00410683.json","name":"LUNG ART","nct_id":"NCT00410683","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery","url":"https://www.erudio.com/trials/lung-art-nct00410683"},{"commentary_sources":54,"json":"https://www.erudio.com/trials/soraya-nct04296890.json","name":"SORAYA","nct_id":"NCT04296890","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","url":"https://www.erudio.com/trials/soraya-nct04296890"},{"commentary_sources":54,"json":"https://www.erudio.com/trials/a-dream-nct05241860.json","name":"A-DREAM","nct_id":"NCT05241860","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)","url":"https://www.erudio.com/trials/a-dream-nct05241860"},{"commentary_sources":54,"json":"https://www.erudio.com/trials/nest-1-nct05571293.json","name":"NEST-1","nct_id":"NCT05571293","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Combination Immunotherapy in Colorectal Cancer","url":"https://www.erudio.com/trials/nest-1-nct05571293"},{"commentary_sources":53,"json":"https://www.erudio.com/trials/l-mind-nct02399085.json","name":"L-MIND","nct_id":"NCT02399085","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL","url":"https://www.erudio.com/trials/l-mind-nct02399085"},{"commentary_sources":53,"json":"https://www.erudio.com/trials/rosewood-nct03332017.json","name":"ROSEWOOD","nct_id":"NCT03332017","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma","url":"https://www.erudio.com/trials/rosewood-nct03332017"},{"commentary_sources":53,"json":"https://www.erudio.com/trials/trade-dxd-nct06533826.json","name":"TRADE DXd","nct_id":"NCT06533826","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","url":"https://www.erudio.com/trials/trade-dxd-nct06533826"},{"commentary_sources":52,"json":"https://www.erudio.com/trials/era-223-nct02043678.json","name":"ERA 223","nct_id":"NCT02043678","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","url":"https://www.erudio.com/trials/era-223-nct02043678"},{"commentary_sources":51,"json":"https://www.erudio.com/trials/alascca-nct02647099.json","name":"ALASCCA","nct_id":"NCT02647099","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Adjuvant Low Dose Aspirin in Colorectal Cancer","url":"https://www.erudio.com/trials/alascca-nct02647099"},{"commentary_sources":51,"json":"https://www.erudio.com/trials/fortitude-101-nct05052801.json","name":"FORTITUDE-101","nct_id":"NCT05052801","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","url":"https://www.erudio.com/trials/fortitude-101-nct05052801"},{"commentary_sources":51,"json":"https://www.erudio.com/trials/immagine-1-nct05396885.json","name":"iMMagine-1","nct_id":"NCT05396885","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)","url":"https://www.erudio.com/trials/immagine-1-nct05396885"},{"commentary_sources":50,"json":"https://www.erudio.com/trials/triton2-nct02952534.json","name":"TRITON2","nct_id":"NCT02952534","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","url":"https://www.erudio.com/trials/triton2-nct02952534"},{"commentary_sources":50,"json":"https://www.erudio.com/trials/karmma-nct03361748.json","name":"KarMMa","nct_id":"NCT03361748","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/karmma-nct03361748"},{"commentary_sources":50,"json":"https://www.erudio.com/trials/nct03553836.json","name":"NCT03553836","nct_id":"NCT03553836","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)","url":"https://www.erudio.com/trials/nct03553836"},{"commentary_sources":50,"json":"https://www.erudio.com/trials/zuma-12-nct03761056.json","name":"ZUMA-12","nct_id":"NCT03761056","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma","url":"https://www.erudio.com/trials/zuma-12-nct03761056"},{"commentary_sources":50,"json":"https://www.erudio.com/trials/cambria-1-nct05774951.json","name":"CAMBRIA-1","nct_id":"NCT05774951","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","url":"https://www.erudio.com/trials/cambria-1-nct05774951"},{"commentary_sources":49,"json":"https://www.erudio.com/trials/checkmate-648-nct03143153.json","name":"CheckMate 648","nct_id":"NCT03143153","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin","url":"https://www.erudio.com/trials/checkmate-648-nct03143153"},{"commentary_sources":49,"json":"https://www.erudio.com/trials/beat-meso-nct03762018.json","name":"BEAT-meso","nct_id":"NCT03762018","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","url":"https://www.erudio.com/trials/beat-meso-nct03762018"},{"commentary_sources":49,"json":"https://www.erudio.com/trials/arc-20-nct05536141.json","name":"ARC-20","nct_id":"NCT05536141","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","url":"https://www.erudio.com/trials/arc-20-nct05536141"},{"commentary_sources":48,"json":"https://www.erudio.com/trials/domenica-nct05201547.json","name":"DOMENICA","nct_id":"NCT05201547","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line","url":"https://www.erudio.com/trials/domenica-nct05201547"},{"commentary_sources":47,"json":"https://www.erudio.com/trials/nct01013649.json","name":"NCT01013649","nct_id":"NCT01013649","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery","url":"https://www.erudio.com/trials/nct01013649"},{"commentary_sources":47,"json":"https://www.erudio.com/trials/nct01150045.json","name":"NCT01150045","nct_id":"NCT01150045","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery","url":"https://www.erudio.com/trials/nct01150045"},{"commentary_sources":47,"json":"https://www.erudio.com/trials/karmma-2-nct03601078.json","name":"KarMMa-2","nct_id":"NCT03601078","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma","url":"https://www.erudio.com/trials/karmma-2-nct03601078"},{"commentary_sources":47,"json":"https://www.erudio.com/trials/nct04185883.json","name":"NCT04185883","nct_id":"NCT04185883","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","url":"https://www.erudio.com/trials/nct04185883"},{"commentary_sources":47,"json":"https://www.erudio.com/trials/checkmate-67t-nct04810078.json","name":"CheckMate-67T","nct_id":"NCT04810078","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread","url":"https://www.erudio.com/trials/checkmate-67t-nct04810078"},{"commentary_sources":46,"json":"https://www.erudio.com/trials/alsympca-nct00699751.json","name":"ALSYMPCA","nct_id":"NCT00699751","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","url":"https://www.erudio.com/trials/alsympca-nct00699751"},{"commentary_sources":46,"json":"https://www.erudio.com/trials/nct02358031.json","name":"NCT02358031","nct_id":"NCT02358031","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","url":"https://www.erudio.com/trials/nct02358031"},{"commentary_sources":46,"json":"https://www.erudio.com/trials/surpass-et-nct04285086.json","name":"SURPASS ET","nct_id":"NCT04285086","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","url":"https://www.erudio.com/trials/surpass-et-nct04285086"},{"commentary_sources":45,"json":"https://www.erudio.com/trials/nct00352846.json","name":"NCT00352846","nct_id":"NCT00352846","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss","url":"https://www.erudio.com/trials/nct00352846"},{"commentary_sources":45,"json":"https://www.erudio.com/trials/radiosa-nct03940235.json","name":"RADIOSA","nct_id":"NCT03940235","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis","url":"https://www.erudio.com/trials/radiosa-nct03940235"},{"commentary_sources":45,"json":"https://www.erudio.com/trials/dasl-hicap-nct04136353.json","name":"DASL-HiCaP","nct_id":"NCT04136353","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","url":"https://www.erudio.com/trials/dasl-hicap-nct04136353"},{"commentary_sources":45,"json":"https://www.erudio.com/trials/stellar-002-nct05176483.json","name":"STELLAR-002","nct_id":"NCT05176483","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors","url":"https://www.erudio.com/trials/stellar-002-nct05176483"},{"commentary_sources":45,"json":"https://www.erudio.com/trials/sunrise-5-nct06211764.json","name":"SunRISe-5","nct_id":"NCT06211764","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","url":"https://www.erudio.com/trials/sunrise-5-nct06211764"},{"commentary_sources":44,"json":"https://www.erudio.com/trials/carmena-nct00930033.json","name":"CARMENA","nct_id":"NCT00930033","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Clinical Trial to Assess the Importance of Nephrectomy","url":"https://www.erudio.com/trials/carmena-nct00930033"},{"commentary_sources":44,"json":"https://www.erudio.com/trials/nct02603341.json","name":"NCT02603341","nct_id":"NCT02603341","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial","url":"https://www.erudio.com/trials/nct02603341"},{"commentary_sources":44,"json":"https://www.erudio.com/trials/successor-1-nct05519085.json","name":"SUCCESSOR-1","nct_id":"NCT05519085","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","url":"https://www.erudio.com/trials/successor-1-nct05519085"},{"commentary_sources":43,"json":"https://www.erudio.com/trials/sameta-nct05043090.json","name":"SAMETA","nct_id":"NCT05043090","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","url":"https://www.erudio.com/trials/sameta-nct05043090"},{"commentary_sources":43,"json":"https://www.erudio.com/trials/nct05226117.json","name":"NCT05226117","nct_id":"NCT05226117","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","url":"https://www.erudio.com/trials/nct05226117"},{"commentary_sources":43,"json":"https://www.erudio.com/trials/sure-02-nct05535218.json","name":"SURE-02","nct_id":"NCT05535218","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer","url":"https://www.erudio.com/trials/sure-02-nct05535218"},{"commentary_sources":42,"json":"https://www.erudio.com/trials/bolero-2-nct00863655.json","name":"BOLERO-2","nct_id":"NCT00863655","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","url":"https://www.erudio.com/trials/bolero-2-nct00863655"},{"commentary_sources":42,"json":"https://www.erudio.com/trials/combi-ad-nct01682083.json","name":"COMBI-AD","nct_id":"NCT01682083","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).","url":"https://www.erudio.com/trials/combi-ad-nct01682083"},{"commentary_sources":42,"json":"https://www.erudio.com/trials/nct04334941.json","name":"NCT04334941","nct_id":"NCT04334941","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker","url":"https://www.erudio.com/trials/nct04334941"},{"commentary_sources":42,"json":"https://www.erudio.com/trials/majestec-4-nct05243797.json","name":"MajesTEC-4","nct_id":"NCT05243797","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","url":"https://www.erudio.com/trials/majestec-4-nct05243797"},{"commentary_sources":41,"json":"https://www.erudio.com/trials/impassion030-nct03498716.json","name":"IMpassion030","nct_id":"NCT03498716","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","url":"https://www.erudio.com/trials/impassion030-nct03498716"},{"commentary_sources":41,"json":"https://www.erudio.com/trials/artemide-nct04839445.json","name":"ARTEMIDE","nct_id":"NCT04839445","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources","title":"ESP vs TAP in Total Laparoscopic Hysterectomy","url":"https://www.erudio.com/trials/artemide-nct04839445"},{"commentary_sources":40,"json":"https://www.erudio.com/trials/nct03523585.json","name":"NCT03523585","nct_id":"NCT03523585","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","url":"https://www.erudio.com/trials/nct03523585"},{"commentary_sources":40,"json":"https://www.erudio.com/trials/iris-nct07510685.json","name":"IRIS","nct_id":"NCT07510685","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)","url":"https://www.erudio.com/trials/iris-nct07510685"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/napoli-1-nct01494506.json","name":"NAPOLI-1","nct_id":"NCT01494506","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer","url":"https://www.erudio.com/trials/napoli-1-nct01494506"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/abc06-nct01926236.json","name":"ABC06","nct_id":"NCT01926236","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers","url":"https://www.erudio.com/trials/abc06-nct01926236"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/freedom2-nct03952039.json","name":"FREEDOM2","nct_id":"NCT03952039","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","url":"https://www.erudio.com/trials/freedom2-nct03952039"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/nct04793958.json","name":"NCT04793958","nct_id":"NCT04793958","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","url":"https://www.erudio.com/trials/nct04793958"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/alneo-nct05015010.json","name":"ALNEO","nct_id":"NCT05015010","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Alectinib in Neo-adjuvant Treatment of Stage III NSCLC","url":"https://www.erudio.com/trials/alneo-nct05015010"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/sachi-nct05015608.json","name":"SACHI","nct_id":"NCT05015608","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification","url":"https://www.erudio.com/trials/sachi-nct05015608"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/nct05629585.json","name":"NCT05629585","nct_id":"NCT05629585","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","url":"https://www.erudio.com/trials/nct05629585"},{"commentary_sources":39,"json":"https://www.erudio.com/trials/nct07085728.json","name":"NCT07085728","nct_id":"NCT07085728","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","url":"https://www.erudio.com/trials/nct07085728"},{"commentary_sources":38,"json":"https://www.erudio.com/trials/s-trac-nct00375674.json","name":"S-TRAC","nct_id":"NCT00375674","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer","url":"https://www.erudio.com/trials/s-trac-nct00375674"},{"commentary_sources":38,"json":"https://www.erudio.com/trials/nct03600883.json","name":"NCT03600883","nct_id":"NCT03600883","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","url":"https://www.erudio.com/trials/nct03600883"},{"commentary_sources":38,"json":"https://www.erudio.com/trials/neopact-nct03639948.json","name":"NeoPACT","nct_id":"NCT03639948","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer","url":"https://www.erudio.com/trials/neopact-nct03639948"},{"commentary_sources":38,"json":"https://www.erudio.com/trials/nct05863195.json","name":"NCT05863195","nct_id":"NCT05863195","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","url":"https://www.erudio.com/trials/nct05863195"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/mindact-nct00433589.json","name":"MINDACT","nct_id":"NCT00433589","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes","url":"https://www.erudio.com/trials/mindact-nct00433589"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/altto-nct00490139.json","name":"ALTTO","nct_id":"NCT00490139","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","url":"https://www.erudio.com/trials/altto-nct00490139"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/extenet-nct00878709.json","name":"ExteNET","nct_id":"NCT00878709","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","url":"https://www.erudio.com/trials/extenet-nct00878709"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/simplify-2-nct02101268.json","name":"Simplify 2","nct_id":"NCT02101268","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","url":"https://www.erudio.com/trials/simplify-2-nct02101268"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/ramp-201-nct04625270.json","name":"RAMP 201","nct_id":"NCT04625270","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation","url":"https://www.erudio.com/trials/ramp-201-nct04625270"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/imbrave251-nct04770896.json","name":"IMbrave251","nct_id":"NCT04770896","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","url":"https://www.erudio.com/trials/imbrave251-nct04770896"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/nct05173987.json","name":"NCT05173987","nct_id":"NCT05173987","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","url":"https://www.erudio.com/trials/nct05173987"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/nct06100874.json","name":"NCT06100874","nct_id":"NCT06100874","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","url":"https://www.erudio.com/trials/nct06100874"},{"commentary_sources":37,"json":"https://www.erudio.com/trials/moonrise-1-nct06319820.json","name":"MoonRISe-1","nct_id":"NCT06319820","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","url":"https://www.erudio.com/trials/moonrise-1-nct06319820"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/ipass-nct00322452.json","name":"IPASS","nct_id":"NCT00322452","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia","url":"https://www.erudio.com/trials/ipass-nct00322452"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/jakarta2-nct01523171.json","name":"JAKARTA2","nct_id":"NCT01523171","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","url":"https://www.erudio.com/trials/jakarta2-nct01523171"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/immotion151-nct02420821.json","name":"IMmotion151","nct_id":"NCT02420821","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)","url":"https://www.erudio.com/trials/immotion151-nct02420821"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/nct03867084.json","name":"NCT03867084","nct_id":"NCT03867084","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)","url":"https://www.erudio.com/trials/nct03867084"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/elm-2-nct03888105.json","name":"ELM-2","nct_id":"NCT03888105","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies","url":"https://www.erudio.com/trials/elm-2-nct03888105"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/cabopoint-nct03945773.json","name":"CaboPoint","nct_id":"NCT03945773","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors","url":"https://www.erudio.com/trials/cabopoint-nct03945773"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/majestec-7-nct05552222.json","name":"MajesTEC-7","nct_id":"NCT05552222","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","url":"https://www.erudio.com/trials/majestec-7-nct05552222"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/libertas-nct05884398.json","name":"LIBERTAS","nct_id":"NCT05884398","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","url":"https://www.erudio.com/trials/libertas-nct05884398"},{"commentary_sources":36,"json":"https://www.erudio.com/trials/nct05933577.json","name":"NCT05933577","nct_id":"NCT05933577","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)","url":"https://www.erudio.com/trials/nct05933577"},{"commentary_sources":35,"json":"https://www.erudio.com/trials/nct02364557.json","name":"NCT02364557","nct_id":"NCT02364557","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival","url":"https://www.erudio.com/trials/nct02364557"},{"commentary_sources":35,"json":"https://www.erudio.com/trials/nct03040999.json","name":"NCT03040999","nct_id":"NCT03040999","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","url":"https://www.erudio.com/trials/nct03040999"},{"commentary_sources":34,"json":"https://www.erudio.com/trials/reach-2-nct02435433.json","name":"REACH-2","nct_id":"NCT02435433","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein","url":"https://www.erudio.com/trials/reach-2-nct02435433"},{"commentary_sources":34,"json":"https://www.erudio.com/trials/nct03367702.json","name":"NCT03367702","nct_id":"NCT03367702","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer","url":"https://www.erudio.com/trials/nct03367702"},{"commentary_sources":34,"json":"https://www.erudio.com/trials/nautika1-nct04302025.json","name":"NAUTIKA1","nct_id":"NCT04302025","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/nautika1-nct04302025"},{"commentary_sources":34,"json":"https://www.erudio.com/trials/keynote-b61-nct04704219.json","name":"KEYNOTE-B61","nct_id":"NCT04704219","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)","url":"https://www.erudio.com/trials/keynote-b61-nct04704219"},{"commentary_sources":33,"json":"https://www.erudio.com/trials/lutectomy-nct04430192.json","name":"LuTectomy","nct_id":"NCT04430192","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy","url":"https://www.erudio.com/trials/lutectomy-nct04430192"},{"commentary_sources":33,"json":"https://www.erudio.com/trials/innovatv-301-nct04697628.json","name":"innovaTV 301","nct_id":"NCT04697628","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","url":"https://www.erudio.com/trials/innovatv-301-nct04697628"},{"commentary_sources":32,"json":"https://www.erudio.com/trials/nct03742297.json","name":"NCT03742297","nct_id":"NCT03742297","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years","url":"https://www.erudio.com/trials/nct03742297"},{"commentary_sources":32,"json":"https://www.erudio.com/trials/cytoshrink-nct04090710.json","name":"CYTOSHRINK","nct_id":"NCT04090710","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer","url":"https://www.erudio.com/trials/cytoshrink-nct04090710"},{"commentary_sources":32,"json":"https://www.erudio.com/trials/preopanc-3-nct04927780.json","name":"PREOPANC-3","nct_id":"NCT04927780","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer","url":"https://www.erudio.com/trials/preopanc-3-nct04927780"},{"commentary_sources":32,"json":"https://www.erudio.com/trials/morningsun-nct05207670.json","name":"MorningSun","nct_id":"NCT05207670","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","url":"https://www.erudio.com/trials/morningsun-nct05207670"},{"commentary_sources":32,"json":"https://www.erudio.com/trials/soho-02-nct06452277.json","name":"SOHO-02","nct_id":"NCT06452277","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","url":"https://www.erudio.com/trials/soho-02-nct06452277"},{"commentary_sources":32,"json":"https://www.erudio.com/trials/rasolute-303-nct07491445.json","name":"RASolute 303","nct_id":"NCT07491445","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","url":"https://www.erudio.com/trials/rasolute-303-nct07491445"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/catnon-nct00626990.json","name":"CATNON","nct_id":"NCT00626990","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)","url":"https://www.erudio.com/trials/catnon-nct00626990"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/echelon-2-nct01777152.json","name":"ECHELON-2","nct_id":"NCT01777152","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas","url":"https://www.erudio.com/trials/echelon-2-nct01777152"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/nct03267433.json","name":"NCT03267433","nct_id":"NCT03267433","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","url":"https://www.erudio.com/trials/nct03267433"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/cosmic-312-nct03755791.json","name":"COSMIC-312","nct_id":"NCT03755791","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","url":"https://www.erudio.com/trials/cosmic-312-nct03755791"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/transcend-fl-nct04245839.json","name":"TRANSCEND FL","nct_id":"NCT04245839","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","url":"https://www.erudio.com/trials/transcend-fl-nct04245839"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/echelon-3-nct04404283.json","name":"ECHELON-3","nct_id":"NCT04404283","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","url":"https://www.erudio.com/trials/echelon-3-nct04404283"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/majestec-2-nct04722146.json","name":"MajesTEC-2","nct_id":"NCT04722146","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma","url":"https://www.erudio.com/trials/majestec-2-nct04722146"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/capitello-292-nct04862663.json","name":"CAPItello-292","nct_id":"NCT04862663","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","url":"https://www.erudio.com/trials/capitello-292-nct04862663"},{"commentary_sources":31,"json":"https://www.erudio.com/trials/pacific-9-nct05221840.json","name":"PACIFIC-9","nct_id":"NCT05221840","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/pacific-9-nct05221840"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/raves-nct00860652.json","name":"RAVES","nct_id":"NCT00860652","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Radiotherapy - Adjuvant Versus Early Salvage","url":"https://www.erudio.com/trials/raves-nct00860652"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/nct02425891.json","name":"NCT02425891","nct_id":"NCT02425891","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)","url":"https://www.erudio.com/trials/nct02425891"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/nct04634877.json","name":"NCT04634877","nct_id":"NCT04634877","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","url":"https://www.erudio.com/trials/nct04634877"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/tuxedo-1-nct04752059.json","name":"TUXEDO-1","nct_id":"NCT04752059","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases","url":"https://www.erudio.com/trials/tuxedo-1-nct04752059"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/evoke-02-nct05186974.json","name":"EVOKE-02","nct_id":"NCT05186974","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/evoke-02-nct05186974"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/psma-dc-nct05939414.json","name":"PSMA-DC","nct_id":"NCT05939414","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","url":"https://www.erudio.com/trials/psma-dc-nct05939414"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/nct06103864.json","name":"NCT06103864","nct_id":"NCT06103864","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)","url":"https://www.erudio.com/trials/nct06103864"},{"commentary_sources":30,"json":"https://www.erudio.com/trials/origami-4-nct06385080.json","name":"OrigAMI-4","nct_id":"NCT06385080","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","url":"https://www.erudio.com/trials/origami-4-nct06385080"},{"commentary_sources":29,"json":"https://www.erudio.com/trials/secombit-nct02631447.json","name":"SECOMBIT","nct_id":"NCT02631447","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Sequential Combo Immuno and Target Therapy (SECOMBIT) Study","url":"https://www.erudio.com/trials/secombit-nct02631447"},{"commentary_sources":29,"json":"https://www.erudio.com/trials/dreamm-3-nct04162210.json","name":"DREAMM-3","nct_id":"NCT04162210","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","url":"https://www.erudio.com/trials/dreamm-3-nct04162210"},{"commentary_sources":29,"json":"https://www.erudio.com/trials/nct05361720.json","name":"NCT05361720","nct_id":"NCT05361720","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study","url":"https://www.erudio.com/trials/nct05361720"},{"commentary_sources":29,"json":"https://www.erudio.com/trials/izalco-nct05704049.json","name":"IZALCO","nct_id":"NCT05704049","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/izalco-nct05704049"},{"commentary_sources":29,"json":"https://www.erudio.com/trials/lucerna-nct06901531.json","name":"LUCERNA","nct_id":"NCT06901531","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","url":"https://www.erudio.com/trials/lucerna-nct06901531"},{"commentary_sources":28,"json":"https://www.erudio.com/trials/amaros-nct00014612.json","name":"AMAROS","nct_id":"NCT00014612","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer","url":"https://www.erudio.com/trials/amaros-nct00014612"},{"commentary_sources":28,"json":"https://www.erudio.com/trials/checkmate-238-nct02388906.json","name":"CheckMate 238","nct_id":"NCT02388906","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma","url":"https://www.erudio.com/trials/checkmate-238-nct02388906"},{"commentary_sources":28,"json":"https://www.erudio.com/trials/atezotribe-nct03721653.json","name":"AtezoTRIBE","nct_id":"NCT03721653","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients","url":"https://www.erudio.com/trials/atezotribe-nct03721653"},{"commentary_sources":28,"json":"https://www.erudio.com/trials/tropion-lung04-nct04612751.json","name":"TROPION-Lung04","nct_id":"NCT04612751","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/tropion-lung04-nct04612751"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/embraca-nct01945775.json","name":"EMBRACA","nct_id":"NCT01945775","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)","url":"https://www.erudio.com/trials/embraca-nct01945775"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/ariel3-nct01968213.json","name":"ARIEL3","nct_id":"NCT01968213","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)","url":"https://www.erudio.com/trials/ariel3-nct01968213"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/zuma-3-nct02614066.json","name":"ZUMA-3","nct_id":"NCT02614066","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)","url":"https://www.erudio.com/trials/zuma-3-nct02614066"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/alta-1l-nct02737501.json","name":"ALTA-1L","nct_id":"NCT02737501","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","url":"https://www.erudio.com/trials/alta-1l-nct02737501"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/oreo-nct03106987.json","name":"OReO","nct_id":"NCT03106987","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.","url":"https://www.erudio.com/trials/oreo-nct03106987"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/cyclone-2-nct03706365.json","name":"CYCLONE 2","nct_id":"NCT03706365","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","url":"https://www.erudio.com/trials/cyclone-2-nct03706365"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/adaura2-nct05120349.json","name":"ADAURA2","nct_id":"NCT05120349","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","url":"https://www.erudio.com/trials/adaura2-nct05120349"},{"commentary_sources":27,"json":"https://www.erudio.com/trials/nct05197192.json","name":"NCT05197192","nct_id":"NCT05197192","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL","url":"https://www.erudio.com/trials/nct05197192"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/nct01668784.json","name":"NCT01668784","nct_id":"NCT01668784","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)","url":"https://www.erudio.com/trials/nct01668784"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/bylieve-nct03056755.json","name":"BYLieve","nct_id":"NCT03056755","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","url":"https://www.erudio.com/trials/bylieve-nct03056755"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/impassion031-nct03197935.json","name":"IMpassion031","nct_id":"NCT03197935","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer","url":"https://www.erudio.com/trials/impassion031-nct03197935"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/fight-302-nct03656536.json","name":"FIGHT-302","nct_id":"NCT03656536","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","url":"https://www.erudio.com/trials/fight-302-nct03656536"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/palmira-nct03809988.json","name":"PALMIRA","nct_id":"NCT03809988","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)","url":"https://www.erudio.com/trials/palmira-nct03809988"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/proof302-nct04197986.json","name":"PROOF302","nct_id":"NCT04197986","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations","url":"https://www.erudio.com/trials/proof302-nct04197986"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/celestimo-nct04712097.json","name":"Celestimo","nct_id":"NCT04712097","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","url":"https://www.erudio.com/trials/celestimo-nct04712097"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/ringside-nct04871282.json","name":"RINGSIDE","nct_id":"NCT04871282","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of AL102 in Patients With Progressing Desmoid Tumors","url":"https://www.erudio.com/trials/ringside-nct04871282"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/oasis-4-nct05587296.json","name":"OASIS-4","nct_id":"NCT05587296","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","url":"https://www.erudio.com/trials/oasis-4-nct05587296"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/avanzar-nct05687266.json","name":"AVANZAR","nct_id":"NCT05687266","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","url":"https://www.erudio.com/trials/avanzar-nct05687266"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/linker-mm4-nct05828511.json","name":"LINKER-MM4","nct_id":"NCT05828511","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","url":"https://www.erudio.com/trials/linker-mm4-nct05828511"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/ofset-nct05879926.json","name":"OFSET","nct_id":"NCT05879926","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","url":"https://www.erudio.com/trials/ofset-nct05879926"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/tropion-lung15-nct06417814.json","name":"TROPION-Lung15","nct_id":"NCT06417814","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/tropion-lung15-nct06417814"},{"commentary_sources":26,"json":"https://www.erudio.com/trials/hera-nct06538337.json","name":"HERA","nct_id":"NCT06538337","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers","url":"https://www.erudio.com/trials/hera-nct06538337"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/planb-nct01049425.json","name":"planB","nct_id":"NCT01049425","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer","url":"https://www.erudio.com/trials/planb-nct01049425"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/de-escalate-nct01874171.json","name":"De-ESCALaTE","nct_id":"NCT01874171","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC","url":"https://www.erudio.com/trials/de-escalate-nct01874171"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/nct02362594.json","name":"NCT02362594","nct_id":"NCT02362594","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","url":"https://www.erudio.com/trials/nct02362594"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/mediola-nct02734004.json","name":"MEDIOLA","nct_id":"NCT02734004","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","url":"https://www.erudio.com/trials/mediola-nct02734004"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/tropics-03-nct03964727.json","name":"TROPiCS-03","nct_id":"NCT03964727","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","url":"https://www.erudio.com/trials/tropics-03-nct03964727"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/mangrove-nct04002297.json","name":"MANGROVE","nct_id":"NCT04002297","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","url":"https://www.erudio.com/trials/mangrove-nct04002297"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/relativity-098-nct05002569.json","name":"RELATIVITY-098","nct_id":"NCT05002569","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma","url":"https://www.erudio.com/trials/relativity-098-nct05002569"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/nct05218499.json","name":"NCT05218499","nct_id":"NCT05218499","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma","url":"https://www.erudio.com/trials/nct05218499"},{"commentary_sources":25,"json":"https://www.erudio.com/trials/nct05555732.json","name":"NCT05555732","nct_id":"NCT05555732","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","url":"https://www.erudio.com/trials/nct05555732"},{"commentary_sources":24,"json":"https://www.erudio.com/trials/nct02048813.json","name":"NCT02048813","nct_id":"NCT02048813","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","url":"https://www.erudio.com/trials/nct02048813"},{"commentary_sources":24,"json":"https://www.erudio.com/trials/portec-4a-nct03469674.json","name":"PORTEC-4a","nct_id":"NCT03469674","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer","url":"https://www.erudio.com/trials/portec-4a-nct03469674"},{"commentary_sources":24,"json":"https://www.erudio.com/trials/reveng-nct04895436.json","name":"ReVenG","nct_id":"NCT04895436","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","url":"https://www.erudio.com/trials/reveng-nct04895436"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/profile-1001-nct00585195.json","name":"PROFILE 1001","nct_id":"NCT00585195","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","url":"https://www.erudio.com/trials/profile-1001-nct00585195"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/monaleesa-7-nct02278120.json","name":"MONALEESA-7","nct_id":"NCT02278120","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","url":"https://www.erudio.com/trials/monaleesa-7-nct02278120"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/tribe2-nct02339116.json","name":"TRIBE2","nct_id":"NCT02339116","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC","url":"https://www.erudio.com/trials/tribe2-nct02339116"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/monaleesa-3-nct02422615.json","name":"MONALEESA-3","nct_id":"NCT02422615","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.","url":"https://www.erudio.com/trials/monaleesa-3-nct02422615"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/lotis-2-nct03589469.json","name":"LOTIS-2","nct_id":"NCT03589469","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","url":"https://www.erudio.com/trials/lotis-2-nct03589469"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/nct04724018.json","name":"NCT04724018","nct_id":"NCT04724018","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Sacituzumab Govitecan Plus EV in Metastatic UC","url":"https://www.erudio.com/trials/nct04724018"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/star-221-nct05568095.json","name":"STAR-221","nct_id":"NCT05568095","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body","url":"https://www.erudio.com/trials/star-221-nct05568095"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/tuxedo-3-nct05865990.json","name":"TUXEDO-3","nct_id":"NCT05865990","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","url":"https://www.erudio.com/trials/tuxedo-3-nct05865990"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/ramp-301-nct06072781.json","name":"RAMP 301","nct_id":"NCT06072781","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","url":"https://www.erudio.com/trials/ramp-301-nct06072781"},{"commentary_sources":23,"json":"https://www.erudio.com/trials/immunoplant-nct06376526.json","name":"IMMUNOPLANT","nct_id":"NCT06376526","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"IMMUNOPLANT for Newly Diagnosed Multiple Myeloma","url":"https://www.erudio.com/trials/immunoplant-nct06376526"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/nct00433927.json","name":"NCT00433927","nct_id":"NCT00433927","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)","url":"https://www.erudio.com/trials/nct00433927"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/ho95-nct01208766.json","name":"HO95","nct_id":"NCT01208766","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","url":"https://www.erudio.com/trials/ho95-nct01208766"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/train-2-nct01996267.json","name":"TRAIN-2","nct_id":"NCT01996267","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","url":"https://www.erudio.com/trials/train-2-nct01996267"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/solo3-nct02282020.json","name":"SOLO3","nct_id":"NCT02282020","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","url":"https://www.erudio.com/trials/solo3-nct02282020"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/nct02919787.json","name":"NCT02919787","nct_id":"NCT02919787","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Nordic Pancreatic Cancer Trial (NorPACT) - 1","url":"https://www.erudio.com/trials/nct02919787"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/clonevo-nct03837821.json","name":"CLONEVO","nct_id":"NCT03837821","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer","url":"https://www.erudio.com/trials/clonevo-nct03837821"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/redose-nct03927391.json","name":"REDOSE","nct_id":"NCT03927391","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects","url":"https://www.erudio.com/trials/redose-nct03927391"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/contact-01-nct04471428.json","name":"CONTACT-01","nct_id":"NCT04471428","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy","url":"https://www.erudio.com/trials/contact-01-nct04471428"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/db-08-nct04556773.json","name":"DB-08","nct_id":"NCT04556773","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","url":"https://www.erudio.com/trials/db-08-nct04556773"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/tropion-lung08-nct05215340.json","name":"TROPION-Lung08","nct_id":"NCT05215340","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","url":"https://www.erudio.com/trials/tropion-lung08-nct05215340"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/magnetismm-6-nct05623020.json","name":"MagnetisMM-6","nct_id":"NCT05623020","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant","url":"https://www.erudio.com/trials/magnetismm-6-nct05623020"},{"commentary_sources":22,"json":"https://www.erudio.com/trials/precoopera-nct05896566.json","name":"PREcoopERA","nct_id":"NCT05896566","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer","url":"https://www.erudio.com/trials/precoopera-nct05896566"},{"commentary_sources":21,"json":"https://www.erudio.com/trials/abc-02-nct00262769.json","name":"ABC-02","nct_id":"NCT00262769","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors","url":"https://www.erudio.com/trials/abc-02-nct00262769"},{"commentary_sources":21,"json":"https://www.erudio.com/trials/nct00644228.json","name":"NCT00644228","nct_id":"NCT00644228","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","url":"https://www.erudio.com/trials/nct00644228"},{"commentary_sources":21,"json":"https://www.erudio.com/trials/geparnuevo-nct02685059.json","name":"GeparNuevo","nct_id":"NCT02685059","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","url":"https://www.erudio.com/trials/geparnuevo-nct02685059"},{"commentary_sources":21,"json":"https://www.erudio.com/trials/impassion131-nct03125902.json","name":"IMpassion131","nct_id":"NCT03125902","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","url":"https://www.erudio.com/trials/impassion131-nct03125902"},{"commentary_sources":21,"json":"https://www.erudio.com/trials/nct03833167.json","name":"NCT03833167","nct_id":"NCT03833167","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)","url":"https://www.erudio.com/trials/nct03833167"},{"commentary_sources":21,"json":"https://www.erudio.com/trials/zuma-22-nct05371093.json","name":"ZUMA-22","nct_id":"NCT05371093","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","url":"https://www.erudio.com/trials/zuma-22-nct05371093"},{"commentary_sources":20,"json":"https://www.erudio.com/trials/aml-17-nct00052299.json","name":"AML-17","nct_id":"NCT00052299","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia","url":"https://www.erudio.com/trials/aml-17-nct00052299"},{"commentary_sources":20,"json":"https://www.erudio.com/trials/peace-iii-nct02194842.json","name":"PEACE III","nct_id":"NCT02194842","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Phase III Radium 223 mCRPC-PEACE III","url":"https://www.erudio.com/trials/peace-iii-nct02194842"},{"commentary_sources":20,"json":"https://www.erudio.com/trials/nct03740165.json","name":"NCT03740165","nct_id":"NCT03740165","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","url":"https://www.erudio.com/trials/nct03740165"},{"commentary_sources":20,"json":"https://www.erudio.com/trials/gbm-agile-nct03970447.json","name":"GBM AGILE","nct_id":"NCT03970447","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","url":"https://www.erudio.com/trials/gbm-agile-nct03970447"},{"commentary_sources":20,"json":"https://www.erudio.com/trials/nct04564703.json","name":"NCT04564703","nct_id":"NCT04564703","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients","url":"https://www.erudio.com/trials/nct04564703"},{"commentary_sources":20,"json":"https://www.erudio.com/trials/nct05327530.json","name":"NCT05327530","nct_id":"NCT05327530","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","url":"https://www.erudio.com/trials/nct05327530"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/nct02292758.json","name":"NCT02292758","nct_id":"NCT02292758","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","url":"https://www.erudio.com/trials/nct02292758"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/impower130-nct02367781.json","name":"IMpower130","nct_id":"NCT02367781","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/impower130-nct02367781"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/opacin-neo-nct02977052.json","name":"OpACIN-neo","nct_id":"NCT02977052","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab","url":"https://www.erudio.com/trials/opacin-neo-nct02977052"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/nct03066778.json","name":"NCT03066778","nct_id":"NCT03066778","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)","url":"https://www.erudio.com/trials/nct03066778"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/ev-201-nct03219333.json","name":"EV-201","nct_id":"NCT03219333","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","url":"https://www.erudio.com/trials/ev-201-nct03219333"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/nct03794544.json","name":"NCT03794544","nct_id":"NCT03794544","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct03794544"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/trust-ii-nct04919811.json","name":"TRUST-II","nct_id":"NCT04919811","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","url":"https://www.erudio.com/trials/trust-ii-nct04919811"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/nct04970901.json","name":"NCT04970901","nct_id":"NCT04970901","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","url":"https://www.erudio.com/trials/nct04970901"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/monumental-2-nct05050097.json","name":"MonumenTAL-2","nct_id":"NCT05050097","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma","url":"https://www.erudio.com/trials/monumental-2-nct05050097"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/fortitude-102-nct05111626.json","name":"FORTITUDE-102","nct_id":"NCT05111626","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","url":"https://www.erudio.com/trials/fortitude-102-nct05111626"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/mountaineer-03-nct05253651.json","name":"MOUNTAINEER-03","nct_id":"NCT05253651","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","url":"https://www.erudio.com/trials/mountaineer-03-nct05253651"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/emerald-y90-nct06040099.json","name":"EMERALD-Y90","nct_id":"NCT06040099","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE","url":"https://www.erudio.com/trials/emerald-y90-nct06040099"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/demether-nct06172127.json","name":"DEMETHER","nct_id":"NCT06172127","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","url":"https://www.erudio.com/trials/demether-nct06172127"},{"commentary_sources":19,"json":"https://www.erudio.com/trials/demeter-nct07786051.json","name":"DEMETER","nct_id":"NCT07786051","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)","url":"https://www.erudio.com/trials/demeter-nct07786051"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/pemcab-nct03534804.json","name":"PemCab","nct_id":"NCT03534804","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma","url":"https://www.erudio.com/trials/pemcab-nct03534804"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/api-cat-nct03692065.json","name":"API-CAT","nct_id":"NCT03692065","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"API-CAT STUDY for APIxaban Cancer Associated Thrombosis","url":"https://www.erudio.com/trials/api-cat-nct03692065"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/ignyte-nct03767348.json","name":"IGNYTE","nct_id":"NCT03767348","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","url":"https://www.erudio.com/trials/ignyte-nct03767348"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/nct03775265.json","name":"NCT03775265","nct_id":"NCT03775265","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","url":"https://www.erudio.com/trials/nct03775265"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/dellphi-306-nct06117774.json","name":"DeLLphi-306","nct_id":"NCT06117774","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","url":"https://www.erudio.com/trials/dellphi-306-nct06117774"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/nct06215118.json","name":"NCT06215118","nct_id":"NCT06215118","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)","url":"https://www.erudio.com/trials/nct06215118"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/nct06520345.json","name":"NCT06520345","nct_id":"NCT06520345","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","url":"https://www.erudio.com/trials/nct06520345"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/quantum-wild-nct06578247.json","name":"QuANTUM-WILD","nct_id":"NCT06578247","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","url":"https://www.erudio.com/trials/quantum-wild-nct06578247"},{"commentary_sources":18,"json":"https://www.erudio.com/trials/origami-5-nct07276399.json","name":"OrigAMI-5","nct_id":"NCT07276399","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","url":"https://www.erudio.com/trials/origami-5-nct07276399"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/nct02927301.json","name":"NCT02927301","nct_id":"NCT02927301","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)","url":"https://www.erudio.com/trials/nct02927301"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/nct03186898.json","name":"NCT03186898","nct_id":"NCT03186898","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer","url":"https://www.erudio.com/trials/nct03186898"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/keynote-799-nct03631784.json","name":"KEYNOTE-799","nct_id":"NCT03631784","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)","url":"https://www.erudio.com/trials/keynote-799-nct03631784"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/keynote-866-nct03924856.json","name":"KEYNOTE-866","nct_id":"NCT03924856","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)","url":"https://www.erudio.com/trials/keynote-866-nct03924856"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/stopgap-nct04762953.json","name":"STOPGAP","nct_id":"NCT04762953","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis","url":"https://www.erudio.com/trials/stopgap-nct04762953"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/arastep-nct05794906.json","name":"ARASTEP","nct_id":"NCT05794906","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","url":"https://www.erudio.com/trials/arastep-nct05794906"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/agni-01-nct06060613.json","name":"Agni-01","nct_id":"NCT06060613","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","url":"https://www.erudio.com/trials/agni-01-nct06060613"},{"commentary_sources":17,"json":"https://www.erudio.com/trials/dellphi-312-nct07005128.json","name":"DeLLphi-312","nct_id":"NCT07005128","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","url":"https://www.erudio.com/trials/dellphi-312-nct07005128"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/portec-2-nct00376844.json","name":"PORTEC-2","nct_id":"NCT00376844","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer","url":"https://www.erudio.com/trials/portec-2-nct00376844"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/keynote-001-nct01295827.json","name":"KEYNOTE-001","nct_id":"NCT01295827","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)","url":"https://www.erudio.com/trials/keynote-001-nct01295827"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/serena-1-nct03616587.json","name":"SERENA-1","nct_id":"NCT03616587","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","url":"https://www.erudio.com/trials/serena-1-nct03616587"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/nct03952585.json","name":"NCT03952585","nct_id":"NCT03952585","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","url":"https://www.erudio.com/trials/nct03952585"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/napoli-3-nct04083235.json","name":"NAPOLI 3","nct_id":"NCT04083235","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","url":"https://www.erudio.com/trials/napoli-3-nct04083235"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/primordium-nct04557059.json","name":"PRIMORDIUM","nct_id":"NCT04557059","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","url":"https://www.erudio.com/trials/primordium-nct04557059"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/adela-nct06382948.json","name":"ADELA","nct_id":"NCT06382948","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","url":"https://www.erudio.com/trials/adela-nct06382948"},{"commentary_sources":16,"json":"https://www.erudio.com/trials/nct06769126.json","name":"NCT06769126","nct_id":"NCT06769126","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study","url":"https://www.erudio.com/trials/nct06769126"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/ascolt-nct00565708.json","name":"ASCOLT","nct_id":"NCT00565708","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers","url":"https://www.erudio.com/trials/ascolt-nct00565708"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/nct01863550.json","name":"NCT01863550","nct_id":"NCT01863550","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","url":"https://www.erudio.com/trials/nct01863550"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/clarinet-forte-nct02651987.json","name":"CLARINET FORTE","nct_id":"NCT02651987","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg","url":"https://www.erudio.com/trials/clarinet-forte-nct02651987"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/checkmate-915-nct03068455.json","name":"CheckMate 915","nct_id":"NCT03068455","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma","url":"https://www.erudio.com/trials/checkmate-915-nct03068455"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/ifm-2018-04-nct03606577.json","name":"IFM 2018-04","nct_id":"NCT03606577","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients","url":"https://www.erudio.com/trials/ifm-2018-04-nct03606577"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/libretto-531-nct04211337.json","name":"LIBRETTO-531","nct_id":"NCT04211337","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","url":"https://www.erudio.com/trials/libretto-531-nct04211337"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/tide-a-nct04698213.json","name":"TIDE-A","nct_id":"NCT04698213","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma","url":"https://www.erudio.com/trials/tide-a-nct04698213"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/enhance-2-nct04778397.json","name":"ENHANCE-2","nct_id":"NCT04778397","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","url":"https://www.erudio.com/trials/enhance-2-nct04778397"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/kandlelit-001-nct05067283.json","name":"KANDLELIT-001","nct_id":"NCT05067283","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","url":"https://www.erudio.com/trials/kandlelit-001-nct05067283"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/nct06111235.json","name":"NCT06111235","nct_id":"NCT06111235","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","url":"https://www.erudio.com/trials/nct06111235"},{"commentary_sources":15,"json":"https://www.erudio.com/trials/pre1005-nct07285239.json","name":"PrE1005","nct_id":"NCT07285239","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","url":"https://www.erudio.com/trials/pre1005-nct07285239"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/nct02166463.json","name":"NCT02166463","nct_id":"NCT02166463","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","url":"https://www.erudio.com/trials/nct02166463"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/neopan-nct02539537.json","name":"NEOPAN","nct_id":"NCT02539537","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma","url":"https://www.erudio.com/trials/neopan-nct02539537"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/ebin-nct03235245.json","name":"EBIN","nct_id":"NCT03235245","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","url":"https://www.erudio.com/trials/ebin-nct03235245"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/mydrug-nct03732703.json","name":"MyDRUG","nct_id":"NCT03732703","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","url":"https://www.erudio.com/trials/mydrug-nct03732703"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/nct03898180.json","name":"NCT03898180","nct_id":"NCT03898180","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)","url":"https://www.erudio.com/trials/nct03898180"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/nct03971474.json","name":"NCT03971474","nct_id":"NCT03971474","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","url":"https://www.erudio.com/trials/nct03971474"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/carmen-lc03-nct04154956.json","name":"CARMEN-LC03","nct_id":"NCT04154956","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","url":"https://www.erudio.com/trials/carmen-lc03-nct04154956"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/enhance-3-nct05079230.json","name":"ENHANCE-3","nct_id":"NCT05079230","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","url":"https://www.erudio.com/trials/enhance-3-nct05079230"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/asc2escalate-nct05384587.json","name":"ASC2ESCALATE","nct_id":"NCT05384587","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","url":"https://www.erudio.com/trials/asc2escalate-nct05384587"},{"commentary_sources":14,"json":"https://www.erudio.com/trials/nexicart-2-nct06097832.json","name":"NEXICART-2","nct_id":"NCT06097832","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis","url":"https://www.erudio.com/trials/nexicart-2-nct06097832"},{"commentary_sources":13,"json":"https://www.erudio.com/trials/nct02105636.json","name":"NCT02105636","nct_id":"NCT02105636","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)","url":"https://www.erudio.com/trials/nct02105636"},{"commentary_sources":13,"json":"https://www.erudio.com/trials/nct02335424.json","name":"NCT02335424","nct_id":"NCT02335424","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)","url":"https://www.erudio.com/trials/nct02335424"},{"commentary_sources":13,"json":"https://www.erudio.com/trials/anvil-nct02595944.json","name":"ANVIL","nct_id":"NCT02595944","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","url":"https://www.erudio.com/trials/anvil-nct02595944"},{"commentary_sources":13,"json":"https://www.erudio.com/trials/nct03425643.json","name":"NCT03425643","nct_id":"NCT03425643","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)","url":"https://www.erudio.com/trials/nct03425643"},{"commentary_sources":13,"json":"https://www.erudio.com/trials/nct04095364.json","name":"NCT04095364","nct_id":"NCT04095364","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","url":"https://www.erudio.com/trials/nct04095364"},{"commentary_sources":13,"json":"https://www.erudio.com/trials/nct06580314.json","name":"NCT06580314","nct_id":"NCT06580314","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","url":"https://www.erudio.com/trials/nct06580314"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/nct01668719.json","name":"NCT01668719","nct_id":"NCT01668719","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma","url":"https://www.erudio.com/trials/nct01668719"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/nct01898494.json","name":"NCT01898494","nct_id":"NCT01898494","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer","url":"https://www.erudio.com/trials/nct01898494"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/aml18-nct02272478.json","name":"AML18","nct_id":"NCT02272478","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","url":"https://www.erudio.com/trials/aml18-nct02272478"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/nct03233711.json","name":"NCT03233711","nct_id":"NCT03233711","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer","url":"https://www.erudio.com/trials/nct03233711"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/footpath-nct03487016.json","name":"FOOTPATH","nct_id":"NCT03487016","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"First-line Therapy in Metastatic PDAC","url":"https://www.erudio.com/trials/footpath-nct03487016"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/ambre-nct04158362.json","name":"AMBRE","nct_id":"NCT04158362","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","url":"https://www.erudio.com/trials/ambre-nct04158362"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/nct04210115.json","name":"NCT04210115","nct_id":"NCT04210115","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","url":"https://www.erudio.com/trials/nct04210115"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/debbrah-nct04420598.json","name":"DEBBRAH","nct_id":"NCT04420598","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease","url":"https://www.erudio.com/trials/debbrah-nct04420598"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/nct04459715.json","name":"NCT04459715","nct_id":"NCT04459715","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)","url":"https://www.erudio.com/trials/nct04459715"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/sorento-nct05050942.json","name":"SORENTO","nct_id":"NCT05050942","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","url":"https://www.erudio.com/trials/sorento-nct05050942"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/rtire-nct05345444.json","name":"RTIRE","nct_id":"NCT05345444","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)","url":"https://www.erudio.com/trials/rtire-nct05345444"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/fontana-nct05797168.json","name":"FONTANA","nct_id":"NCT05797168","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","url":"https://www.erudio.com/trials/fontana-nct05797168"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/poiesis-nct06479135.json","name":"POIESIS","nct_id":"NCT06479135","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","url":"https://www.erudio.com/trials/poiesis-nct06479135"},{"commentary_sources":12,"json":"https://www.erudio.com/trials/inavo123-nct06790693.json","name":"INAVO123","nct_id":"NCT06790693","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","url":"https://www.erudio.com/trials/inavo123-nct06790693"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/nct01169337.json","name":"NCT01169337","nct_id":"NCT01169337","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma","url":"https://www.erudio.com/trials/nct01169337"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/geparsixto-nct01426880.json","name":"GeparSixto","nct_id":"NCT01426880","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer","url":"https://www.erudio.com/trials/geparsixto-nct01426880"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/nct01824875.json","name":"NCT01824875","nct_id":"NCT01824875","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors","url":"https://www.erudio.com/trials/nct01824875"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/ampect-nct02494570.json","name":"AMPECT","nct_id":"NCT02494570","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa","url":"https://www.erudio.com/trials/ampect-nct02494570"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/cantata-nct03428217.json","name":"CANTATA","nct_id":"NCT03428217","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma","url":"https://www.erudio.com/trials/cantata-nct03428217"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/beatcc-nct03556839.json","name":"BEATcc","nct_id":"NCT03556839","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix","url":"https://www.erudio.com/trials/beatcc-nct03556839"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/vesalius-cv-nct03872401.json","name":"VESALIUS-CV","nct_id":"NCT03872401","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","url":"https://www.erudio.com/trials/vesalius-cv-nct03872401"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/nct03914625.json","name":"NCT03914625","nct_id":"NCT03914625","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","url":"https://www.erudio.com/trials/nct03914625"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/astefania-nct04873362.json","name":"Astefania","nct_id":"NCT04873362","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","url":"https://www.erudio.com/trials/astefania-nct04873362"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/arasec-nct05059236.json","name":"ARASEC","nct_id":"NCT05059236","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","url":"https://www.erudio.com/trials/arasec-nct05059236"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/bexmab-nct05428969.json","name":"BEXMAB","nct_id":"NCT05428969","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","url":"https://www.erudio.com/trials/bexmab-nct05428969"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/nct06337318.json","name":"NCT06337318","nct_id":"NCT06337318","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","url":"https://www.erudio.com/trials/nct06337318"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/destiny-btc01-nct06467357.json","name":"DESTINY-BTC01","nct_id":"NCT06467357","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","url":"https://www.erudio.com/trials/destiny-btc01-nct06467357"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/nct06615479.json","name":"NCT06615479","nct_id":"NCT06615479","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","url":"https://www.erudio.com/trials/nct06615479"},{"commentary_sources":11,"json":"https://www.erudio.com/trials/dreamm-10-nct06679101.json","name":"DREAMM-10","nct_id":"NCT06679101","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","url":"https://www.erudio.com/trials/dreamm-10-nct06679101"},{"commentary_sources":10,"json":"https://www.erudio.com/trials/nct02414139.json","name":"NCT02414139","nct_id":"NCT02414139","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","url":"https://www.erudio.com/trials/nct02414139"},{"commentary_sources":10,"json":"https://www.erudio.com/trials/nct03302234.json","name":"NCT03302234","nct_id":"NCT03302234","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)","url":"https://www.erudio.com/trials/nct03302234"},{"commentary_sources":10,"json":"https://www.erudio.com/trials/pacific-5-nct03706690.json","name":"PACIFIC-5","nct_id":"NCT03706690","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","url":"https://www.erudio.com/trials/pacific-5-nct03706690"},{"commentary_sources":10,"json":"https://www.erudio.com/trials/nct03834961.json","name":"NCT03834961","nct_id":"NCT03834961","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia","url":"https://www.erudio.com/trials/nct03834961"},{"commentary_sources":10,"json":"https://www.erudio.com/trials/patapsco-nct05943106.json","name":"PATAPSCO","nct_id":"NCT05943106","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","url":"https://www.erudio.com/trials/patapsco-nct05943106"},{"commentary_sources":10,"json":"https://www.erudio.com/trials/nct06567743.json","name":"NCT06567743","nct_id":"NCT06567743","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","url":"https://www.erudio.com/trials/nct06567743"},{"commentary_sources":10,"json":"https://www.erudio.com/trials/moonrise-3-nct06919965.json","name":"MoonRISe-3","nct_id":"NCT06919965","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","url":"https://www.erudio.com/trials/moonrise-3-nct06919965"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/radiant-2-nct00412061.json","name":"RADIANT-2","nct_id":"NCT00412061","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor","url":"https://www.erudio.com/trials/radiant-2-nct00412061"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/nct00861705.json","name":"NCT00861705","nct_id":"NCT00861705","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery","url":"https://www.erudio.com/trials/nct00861705"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/profile-1014-nct01154140.json","name":"PROFILE 1014","nct_id":"NCT01154140","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung","url":"https://www.erudio.com/trials/profile-1014-nct01154140"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/faktion-nct01992952.json","name":"FAKTION","nct_id":"NCT01992952","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer","url":"https://www.erudio.com/trials/faktion-nct01992952"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/nct02143466.json","name":"NCT02143466","nct_id":"NCT02143466","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","url":"https://www.erudio.com/trials/nct02143466"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/beacon-crc-nct02928224.json","name":"BEACON CRC","nct_id":"NCT02928224","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","url":"https://www.erudio.com/trials/beacon-crc-nct02928224"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/nct03052608.json","name":"NCT03052608","nct_id":"NCT03052608","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","url":"https://www.erudio.com/trials/nct03052608"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/checkmate-9dx-nct03383458.json","name":"CheckMate 9DX","nct_id":"NCT03383458","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","url":"https://www.erudio.com/trials/checkmate-9dx-nct03383458"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/federica-nct03493854.json","name":"FeDeriCa","nct_id":"NCT03493854","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","url":"https://www.erudio.com/trials/federica-nct03493854"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/mithridate-nct04116502.json","name":"MITHRIDATE","nct_id":"NCT04116502","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","url":"https://www.erudio.com/trials/mithridate-nct04116502"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/karmma-4-nct04196491.json","name":"KarMMa-4","nct_id":"NCT04196491","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)","url":"https://www.erudio.com/trials/karmma-4-nct04196491"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/lotis-5-nct04384484.json","name":"LOTIS 5","nct_id":"NCT04384484","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","url":"https://www.erudio.com/trials/lotis-5-nct04384484"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/veritac-3-nct05909397.json","name":"VERITAC-3","nct_id":"NCT05909397","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","url":"https://www.erudio.com/trials/veritac-3-nct05909397"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/stopnet-nct06345079.json","name":"STOPNET","nct_id":"NCT06345079","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","url":"https://www.erudio.com/trials/stopnet-nct06345079"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/solara-nct06706076.json","name":"SOLARA","nct_id":"NCT06706076","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","url":"https://www.erudio.com/trials/solara-nct06706076"},{"commentary_sources":9,"json":"https://www.erudio.com/trials/rasolute-304-nct07252232.json","name":"RASolute 304","nct_id":"NCT07252232","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","url":"https://www.erudio.com/trials/rasolute-304-nct07252232"},{"commentary_sources":8,"json":"https://www.erudio.com/trials/nct00632853.json","name":"NCT00632853","nct_id":"NCT00632853","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide","url":"https://www.erudio.com/trials/nct00632853"},{"commentary_sources":8,"json":"https://www.erudio.com/trials/flot3-nct00849615.json","name":"FLOT3","nct_id":"NCT00849615","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","url":"https://www.erudio.com/trials/flot3-nct00849615"},{"commentary_sources":8,"json":"https://www.erudio.com/trials/nct00929591.json","name":"NCT00929591","nct_id":"NCT00929591","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer","url":"https://www.erudio.com/trials/nct00929591"},{"commentary_sources":8,"json":"https://www.erudio.com/trials/nct01287741.json","name":"NCT01287741","nct_id":"NCT01287741","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)","url":"https://www.erudio.com/trials/nct01287741"},{"commentary_sources":8,"json":"https://www.erudio.com/trials/nct02513186.json","name":"NCT02513186","nct_id":"NCT02513186","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","url":"https://www.erudio.com/trials/nct02513186"},{"commentary_sources":8,"json":"https://www.erudio.com/trials/nct04115631.json","name":"NCT04115631","nct_id":"NCT04115631","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","url":"https://www.erudio.com/trials/nct04115631"},{"commentary_sources":8,"json":"https://www.erudio.com/trials/paxipem-nct05096390.json","name":"PAXIPEM","nct_id":"NCT05096390","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC","url":"https://www.erudio.com/trials/paxipem-nct05096390"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/icon8-nct01654146.json","name":"ICON8","nct_id":"NCT01654146","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"ICON8: Weekly Chemotherapy in Ovarian Cancer","url":"https://www.erudio.com/trials/icon8-nct01654146"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/opacin-nct02437279.json","name":"OpACIN","nct_id":"NCT02437279","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients","url":"https://www.erudio.com/trials/opacin-nct02437279"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/nct03055013.json","name":"NCT03055013","nct_id":"NCT03055013","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy","url":"https://www.erudio.com/trials/nct03055013"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/nct03269136.json","name":"NCT03269136","nct_id":"NCT03269136","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/nct03269136"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/laura-nct03521154.json","name":"LAURA","nct_id":"NCT03521154","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)","url":"https://www.erudio.com/trials/laura-nct03521154"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/trio-nct03978663.json","name":"TRIO","nct_id":"NCT03978663","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Three Fraction Radiation to Induce Immuno-Oncologic Response","url":"https://www.erudio.com/trials/trio-nct03978663"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/nct04164901.json","name":"NCT04164901","nct_id":"NCT04164901","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)","url":"https://www.erudio.com/trials/nct04164901"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/nct04277637.json","name":"NCT04277637","nct_id":"NCT04277637","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","url":"https://www.erudio.com/trials/nct04277637"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/db-07-nct04538742.json","name":"DB-07","nct_id":"NCT04538742","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","url":"https://www.erudio.com/trials/db-07-nct04538742"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/nct04886804.json","name":"NCT04886804","nct_id":"NCT04886804","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","url":"https://www.erudio.com/trials/nct04886804"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/nct05256225.json","name":"NCT05256225","nct_id":"NCT05256225","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","url":"https://www.erudio.com/trials/nct05256225"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/cyclone-3-nct05288166.json","name":"CYCLONE 3","nct_id":"NCT05288166","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","url":"https://www.erudio.com/trials/cyclone-3-nct05288166"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/waveline-007-nct05406401.json","name":"waveLINE-007","nct_id":"NCT05406401","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","url":"https://www.erudio.com/trials/waveline-007-nct05406401"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/melt-mm-nct06645678.json","name":"MELT-MM","nct_id":"NCT06645678","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/melt-mm-nct06645678"},{"commentary_sources":7,"json":"https://www.erudio.com/trials/stellar-311-nct06943755.json","name":"STELLAR-311","nct_id":"NCT06943755","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","url":"https://www.erudio.com/trials/stellar-311-nct06943755"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/nct00003389.json","name":"NCT00003389","nct_id":"NCT00003389","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","url":"https://www.erudio.com/trials/nct00003389"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/nct01572480.json","name":"NCT01572480","nct_id":"NCT01572480","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","url":"https://www.erudio.com/trials/nct01572480"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/velia-nct02470585.json","name":"VELIA","nct_id":"NCT02470585","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","url":"https://www.erudio.com/trials/velia-nct02470585"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/forward-i-nct02631876.json","name":"FORWARD I","nct_id":"NCT02631876","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","url":"https://www.erudio.com/trials/forward-i-nct02631876"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/clover-wam-nct02952508.json","name":"CLOVER-WaM","nct_id":"NCT02952508","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","url":"https://www.erudio.com/trials/clover-wam-nct02952508"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/nct02954874.json","name":"NCT02954874","nct_id":"NCT02954874","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","url":"https://www.erudio.com/trials/nct02954874"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/adriatic-nct03703297.json","name":"ADRIATIC","nct_id":"NCT03703297","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy","url":"https://www.erudio.com/trials/adriatic-nct03703297"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/nct03738228.json","name":"NCT03738228","nct_id":"NCT03738228","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer","url":"https://www.erudio.com/trials/nct03738228"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/pivot-10-nct03785925.json","name":"PIVOT-10","nct_id":"NCT03785925","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer","url":"https://www.erudio.com/trials/pivot-10-nct03785925"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/nct04025879.json","name":"NCT04025879","nct_id":"NCT04025879","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct04025879"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/torchlight-nct04085276.json","name":"TORCHLIGHT","nct_id":"NCT04085276","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment","url":"https://www.erudio.com/trials/torchlight-nct04085276"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/artacus-nct04349436.json","name":"ARTACUS","nct_id":"NCT04349436","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","url":"https://www.erudio.com/trials/artacus-nct04349436"},{"commentary_sources":6,"json":"https://www.erudio.com/trials/nct04956640.json","name":"NCT04956640","nct_id":"NCT04956640","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","url":"https://www.erudio.com/trials/nct04956640"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct00887198.json","name":"NCT00887198","nct_id":"NCT00887198","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","url":"https://www.erudio.com/trials/nct00887198"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct01631552.json","name":"NCT01631552","nct_id":"NCT01631552","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","url":"https://www.erudio.com/trials/nct01631552"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/monarch-1-nct02102490.json","name":"MONARCH 1","nct_id":"NCT02102490","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread","url":"https://www.erudio.com/trials/monarch-1-nct02102490"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/checkmate-920-nct02982954.json","name":"CHECKMATE 920","nct_id":"NCT02982954","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer","url":"https://www.erudio.com/trials/checkmate-920-nct02982954"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct03384940.json","name":"NCT03384940","nct_id":"NCT03384940","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)","url":"https://www.erudio.com/trials/nct03384940"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct03456076.json","name":"NCT03456076","nct_id":"NCT03456076","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct03456076"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/mariposa-nct04487080.json","name":"MARIPOSA","nct_id":"NCT04487080","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/mariposa-nct04487080"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/papillon-nct04538664.json","name":"PAPILLON","nct_id":"NCT04538664","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","url":"https://www.erudio.com/trials/papillon-nct04538664"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/sentry-nct04562389.json","name":"SENTRY","nct_id":"NCT04562389","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","url":"https://www.erudio.com/trials/sentry-nct04562389"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct04592913.json","name":"NCT04592913","nct_id":"NCT04592913","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","url":"https://www.erudio.com/trials/nct04592913"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct05099172.json","name":"NCT05099172","nct_id":"NCT05099172","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)","url":"https://www.erudio.com/trials/nct05099172"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct05112601.json","name":"NCT05112601","nct_id":"NCT05112601","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","url":"https://www.erudio.com/trials/nct05112601"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/verify-nct05210790.json","name":"VERIFY","nct_id":"NCT05210790","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera","url":"https://www.erudio.com/trials/verify-nct05210790"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct05256290.json","name":"NCT05256290","nct_id":"NCT05256290","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","url":"https://www.erudio.com/trials/nct05256290"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct05410145.json","name":"NCT05410145","nct_id":"NCT05410145","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","url":"https://www.erudio.com/trials/nct05410145"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct05631262.json","name":"NCT05631262","nct_id":"NCT05631262","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","url":"https://www.erudio.com/trials/nct05631262"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/nct05840016.json","name":"NCT05840016","nct_id":"NCT05840016","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct05840016"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/triton-nct06008093.json","name":"TRITON","nct_id":"NCT06008093","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","url":"https://www.erudio.com/trials/triton-nct06008093"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/starlight-1-nct06343311.json","name":"STARLIGHT-1","nct_id":"NCT06343311","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","url":"https://www.erudio.com/trials/starlight-1-nct06343311"},{"commentary_sources":5,"json":"https://www.erudio.com/trials/survive-heroes-nct06643585.json","name":"SURVIVE HERoes","nct_id":"NCT06643585","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","url":"https://www.erudio.com/trials/survive-heroes-nct06643585"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct02193282.json","name":"NCT02193282","nct_id":"NCT02193282","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","url":"https://www.erudio.com/trials/nct02193282"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct02271828.json","name":"NCT02271828","nct_id":"NCT02271828","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy","url":"https://www.erudio.com/trials/nct02271828"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/checkmate-651-nct02741570.json","name":"CheckMate 651","nct_id":"NCT02741570","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","url":"https://www.erudio.com/trials/checkmate-651-nct02741570"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct02912559.json","name":"NCT02912559","nct_id":"NCT02912559","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","url":"https://www.erudio.com/trials/nct02912559"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct02952586.json","name":"NCT02952586","nct_id":"NCT02952586","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)","url":"https://www.erudio.com/trials/nct02952586"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/ambassador-nct03244384.json","name":"AMBASSADOR","nct_id":"NCT03244384","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","url":"https://www.erudio.com/trials/ambassador-nct03244384"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/fort-2-nct03473756.json","name":"FORT-2","nct_id":"NCT03473756","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma","url":"https://www.erudio.com/trials/fort-2-nct03473756"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/dreamm-7-nct04246047.json","name":"DREAMM 7","nct_id":"NCT04246047","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","url":"https://www.erudio.com/trials/dreamm-7-nct04246047"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct04613596.json","name":"NCT04613596","nct_id":"NCT04613596","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","url":"https://www.erudio.com/trials/nct04613596"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nero-nct05455424.json","name":"NERO","nct_id":"NCT05455424","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Niraparib Efficacy in Patient With Unresectable Mesothelioma","url":"https://www.erudio.com/trials/nero-nct05455424"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct05599984.json","name":"NCT05599984","nct_id":"NCT05599984","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","url":"https://www.erudio.com/trials/nct05599984"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct05740943.json","name":"NCT05740943","nct_id":"NCT05740943","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Induction Lorlatinib in Stage III Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct05740943"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/archer-nct05950139.json","name":"ARCHER","nct_id":"NCT05950139","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC","url":"https://www.erudio.com/trials/archer-nct05950139"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/sunray-01-nct06119581.json","name":"SUNRAY-01","nct_id":"NCT06119581","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/sunray-01-nct06119581"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct06343402.json","name":"NCT06343402","nct_id":"NCT06343402","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct06343402"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct06361927.json","name":"NCT06361927","nct_id":"NCT06361927","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients","url":"https://www.erudio.com/trials/nct06361927"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/lider-nct06385548.json","name":"LiDer","nct_id":"NCT06385548","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer","url":"https://www.erudio.com/trials/lider-nct06385548"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct06385925.json","name":"NCT06385925","nct_id":"NCT06385925","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","url":"https://www.erudio.com/trials/nct06385925"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct06478043.json","name":"NCT06478043","nct_id":"NCT06478043","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC","url":"https://www.erudio.com/trials/nct06478043"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct06500026.json","name":"NCT06500026","nct_id":"NCT06500026","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","url":"https://www.erudio.com/trials/nct06500026"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/copernicus-nct06667076.json","name":"COPERNICUS","nct_id":"NCT06667076","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/copernicus-nct06667076"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct06712316.json","name":"NCT06712316","nct_id":"NCT06712316","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","url":"https://www.erudio.com/trials/nct06712316"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/versatile-003-nct06790966.json","name":"VERSATILE-003","nct_id":"NCT06790966","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","url":"https://www.erudio.com/trials/versatile-003-nct06790966"},{"commentary_sources":4,"json":"https://www.erudio.com/trials/nct06905197.json","name":"NCT06905197","nct_id":"NCT06905197","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)","url":"https://www.erudio.com/trials/nct06905197"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct00030771.json","name":"NCT00030771","nct_id":"NCT00030771","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients","url":"https://www.erudio.com/trials/nct00030771"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/ha-pci-nct01780675.json","name":"HA-PCI","nct_id":"NCT01780675","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Hippocampus Avoidance PCI vs PCI","url":"https://www.erudio.com/trials/ha-pci-nct01780675"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct02273375.json","name":"NCT02273375","nct_id":"NCT02273375","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC","url":"https://www.erudio.com/trials/nct02273375"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/ontrk-nct03182257.json","name":"ONTRK","nct_id":"NCT03182257","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors","url":"https://www.erudio.com/trials/ontrk-nct03182257"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct03301220.json","name":"NCT03301220","nct_id":"NCT03301220","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","url":"https://www.erudio.com/trials/nct03301220"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct03375320.json","name":"NCT03375320","nct_id":"NCT03375320","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","url":"https://www.erudio.com/trials/nct03375320"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct03539536.json","name":"NCT03539536","nct_id":"NCT03539536","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct03539536"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/proteus-nct03767244.json","name":"PROTEUS","nct_id":"NCT03767244","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","url":"https://www.erudio.com/trials/proteus-nct03767244"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/gen602-nct03775525.json","name":"GEN602","nct_id":"NCT03775525","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer","url":"https://www.erudio.com/trials/gen602-nct03775525"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/aegean-nct03800134.json","name":"AEGEAN","nct_id":"NCT03800134","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/aegean-nct03800134"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/libretto-121-nct03899792.json","name":"LIBRETTO-121","nct_id":"NCT03899792","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","url":"https://www.erudio.com/trials/libretto-121-nct03899792"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/europa-nct04134598.json","name":"EUROPA","nct_id":"NCT04134598","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer","url":"https://www.erudio.com/trials/europa-nct04134598"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct04162015.json","name":"NCT04162015","nct_id":"NCT04162015","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma","url":"https://www.erudio.com/trials/nct04162015"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/acceleret-lung-nct04222972.json","name":"AcceleRET-Lung","nct_id":"NCT04222972","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","url":"https://www.erudio.com/trials/acceleret-lung-nct04222972"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/top-nct04695925.json","name":"TOP","nct_id":"NCT04695925","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations","url":"https://www.erudio.com/trials/top-nct04695925"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/flame-nct04769388.json","name":"FLAME","nct_id":"NCT04769388","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib","url":"https://www.erudio.com/trials/flame-nct04769388"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/icarus-lung01-nct04940325.json","name":"ICARUS-LUNG01","nct_id":"NCT04940325","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/icarus-lung01-nct04940325"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/luca-merit-1-nct05142189.json","name":"LuCa-MERIT-1","nct_id":"NCT05142189","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","url":"https://www.erudio.com/trials/luca-merit-1-nct05142189"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/pavo-nct05169437.json","name":"PAVO","nct_id":"NCT05169437","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors","url":"https://www.erudio.com/trials/pavo-nct05169437"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05236946.json","name":"NCT05236946","nct_id":"NCT05236946","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","url":"https://www.erudio.com/trials/nct05236946"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05265091.json","name":"NCT05265091","nct_id":"NCT05265091","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of KL590586 in Patients With Advanced Solid Tumors","url":"https://www.erudio.com/trials/nct05265091"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05382559.json","name":"NCT05382559","nct_id":"NCT05382559","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","url":"https://www.erudio.com/trials/nct05382559"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05384626.json","name":"NCT05384626","nct_id":"NCT05384626","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","url":"https://www.erudio.com/trials/nct05384626"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/latify-nct05450692.json","name":"LATIFY","nct_id":"NCT05450692","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","url":"https://www.erudio.com/trials/latify-nct05450692"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05561387.json","name":"NCT05561387","nct_id":"NCT05561387","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","url":"https://www.erudio.com/trials/nct05561387"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05675410.json","name":"NCT05675410","nct_id":"NCT05675410","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","url":"https://www.erudio.com/trials/nct05675410"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/krascendo-170-nct05789082.json","name":"KRAScendo 170","nct_id":"NCT05789082","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","url":"https://www.erudio.com/trials/krascendo-170-nct05789082"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05879978.json","name":"NCT05879978","nct_id":"NCT05879978","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","url":"https://www.erudio.com/trials/nct05879978"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct05987241.json","name":"NCT05987241","nct_id":"NCT05987241","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study","url":"https://www.erudio.com/trials/nct05987241"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct06115642.json","name":"NCT06115642","nct_id":"NCT06115642","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","url":"https://www.erudio.com/trials/nct06115642"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/neovade-nct06300424.json","name":"NEOVADE","nct_id":"NCT06300424","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC","url":"https://www.erudio.com/trials/neovade-nct06300424"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct06437509.json","name":"NCT06437509","nct_id":"NCT06437509","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct06437509"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct06448312.json","name":"NCT06448312","nct_id":"NCT06448312","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://www.erudio.com/trials/nct06448312"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/evenet-nct06472388.json","name":"EVENET","nct_id":"NCT06472388","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors","url":"https://www.erudio.com/trials/evenet-nct06472388"},{"commentary_sources":3,"json":"https://www.erudio.com/trials/nct06500676.json","name":"NCT06500676","nct_id":"NCT06500676","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources","title":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","url":"https://www.erudio.com/trials/nct06500676"}]}